

Guidelines on Non-muscle-invasive **Bladder Cancer** (Ta, T1 and CIS)

M. Babjuk (Chair), A. Böhle, M. Burger, E. Compérat,
E. Kaasinen, J. Palou, M. Rouprêt, B.W.G. van Rhijn, S. Shariat,
R. Sylvester, R. Zigeuner

TABLE OF CONTENTS

PAGE

1.	INTRODUCTION	4
1.1	Aims and scope	4
1.2	Panel composition	4
1.3	Available publications	4
1.4	Publication history and summary of changes	4
1.4.1	Publication history	4
1.4.2	Summary of changes	4
2.	METHODS	5
2.1	Data Identification	5
2.2	Review	5
3.	EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY	5
3.1	Epidemiology	5
3.2	Aetiology	6
3.3	Pathology	6
4.	STAGING AND CLASSIFICATION SYSTEMS	6
4.1	Definition of non-muscle-invasive bladder cancer	6
4.2	Tumour, Node, Metastasis Classification (TNM)	6
4.3	Histological grading of non-muscle-invasive bladder urothelial carcinomas	7
4.4	CIS and its classification	8
4.5	Inter- and intra-observer variability in staging and grading	8
4.6	Further promising pathology parameters	8
4.7	Recommendations	9
5.	DIAGNOSIS	9
5.1	Patient history	9
5.2	Signs and symptoms	9
5.3	Physical examination	9
5.4	Imaging	9
5.4.1	Computed tomography urography and intravenous urography	9
5.4.2	Ultrasound (US)	9
5.5	Urinary cytology	9
5.6	Urinary molecular marker tests	9
5.7	Potential application of urinary cytology and markers	10
5.7.1	Screening of the population at risk of BC	10
5.7.2	Exploration of patients after haematuria or other symptoms suggestive of BC (primary detection)	10
5.7.3	Surveillance of NMIBC	10
5.7.3.1	Follow-up of high-risk NMIBC	10
5.7.3.2	Follow-up of low-/intermediate-risk NMIBC	10
5.8	Cystoscopy	10
5.9	Guidelines for the primary assessment of NMIBC	11
5.10	Transurethral resection of Ta, T1 bladder tumours	11
5.10.1	Strategy of the procedure	11
5.10.2	Office-based fulguration	12
5.10.3	New resection techniques	12
5.10.4	Bladder and prostatic urethral biopsies	12
5.11	New methods of tumour visualization	12
5.11.1	Photodynamic diagnosis (fluorescence cystoscopy)	12
5.11.2	Narrow-band imaging	12
5.12	Second resection	12
5.13	Pathology report	13
5.14	Guidelines for TURB and/or biopsies, tumour classification and pathology report	13

6.	PREDICTING DISEASE RECURRENCE AND PROGRESSION	14
6.1	Ta, T1 tumours	14
6.2	Carcinoma <i>in situ</i>	16
6.3	Patients' stratification into risk groups	16
6.3.1	Recommendations for stratification of NMIBC	17
7.	DISEASE MANAGEMENT	17
7.1	Counselling of smoking cessation	17
7.2	Adjuvant treatment	17
7.2.1	Intravesical chemotherapy	17
7.2.1.1	A single, immediate, post-operative intravesical instillation of chemotherapy	17
7.2.1.2	Additional adjuvant intravesical chemotherapy instillations	17
7.2.1.3	Options for improving efficacy of intravesical chemotherapy	18
7.2.2	Intravesical bacillus Calmette-Guérin (BCG) immunotherapy	18
7.2.2.1	Efficacy of BCG	18
7.2.2.2	BCG strain	19
7.2.2.3	BCG toxicity	19
7.2.2.4	Optimal BCG schedule	20
7.2.2.5	Optimal dose of BCG	20
7.2.2.6	Indications for BCG	20
7.2.3	Specific aspects of treatment of CIS	21
7.2.3.1	Treatment strategy	21
7.2.3.2	Cohort studies on intravesical BCG or chemotherapy	21
7.2.3.3	Prospective randomized trials on intravesical BCG or chemotherapy	21
7.2.3.4	Treatment of extravesical CIS	21
7.3	Treatment of failure of intravesical therapy	23
7.3.1	Failure of intravesical chemotherapy	23
7.3.2	Recurrence and failure after intravesical BCG immunotherapy	23
7.3.3	Treatment of BCG failure and recurrences after BCG	23
7.4	Radical cystectomy for NMIBC	24
7.5	Recommendations for adjuvant therapy in Ta, T1 tumours and for therapy of CIS	26
8.	FOLLOW-UP OF PATIENTS WITH NMIBC	26
8.1	Guidelines for follow-up in patients after TURB of NMIBC	27
9.	REFERENCES	28
10.	CONFLICT OF INTEREST	38

1. INTRODUCTION

1.1 Aims and scope

This overview represents the updated European Association of Urology (EAU) guidelines for Non-muscle-invasive Bladder Cancer (NMIBC) Ta, T1 and CIS. The information presented is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical guidance on the clinical management of NMIBC with a focus on clinical presentation and recommendations.

Separate EAU guidelines documents are available addressing upper tract urothelial carcinomas (UTUCs) [1], muscle-invasive and metastatic bladder cancer (MIBC) [2], and primary urethral carcinomas [3].

1.2 Panel composition

The EAU Guidelines Panel on NMIBC consists of an international multidisciplinary group of clinicians, including a pathologist and a statistician. Members of this panel have been selected based on their expertise and to represent the professionals treating patients suspected of harbouring bladder cancer.

All experts involved in the production of this document have submitted potential conflict of interest statements.

1.3 Available publications

A quick reference document (Pocket guidelines) is available, both in print and in a number of versions for mobile devices, presenting the main findings of the NMIBC Guidelines. These are abridged versions which may require consultation together with the full text versions. Several scientific publications are available, as are a number of translations of all versions of the EAU NMIBC Guidelines. All documents can be accessed through the EAU website Uroweb: <http://www.uroweb.org/guidelines/online-guidelines/>.

1.4 Publication history and summary of changes

1.4.1 Publication history

The first EAU Guidelines on Bladder Cancer were published in 2000. This 2015 MIBC guidelines document presents a limited update of the 2014 full text document.

1.4.2 Summary of changes

Key changes for this 2015 print:

- The literature for the complete document has been assessed and updated, whenever relevant.
- A new section on resection techniques has been added, also expanding on the significance of biopsy for bladder cancer pathology.
- The sections on the role of imaging for initial diagnosis and follow-up have been updated.
- The sections on stratification of patients into risk groups and high-risk disease have been enlarged.
- A new section on Bacillus Calmette-Guérin (BCG) is included and the section on intravesical BCG and immunotherapy schedule has been expanded in this 2015 version of the NMIBC Guidelines.

Recommendations have been rephrased and added to throughout the current document, not resulting in a change in the grade of recommendation (GR). New recommendations have been included in sections:

5.14 Guidelines for TURB and/or biopsies, tumour classification and pathology report

	GR
Avoid cauterization as much as possible during TURB to avoid tissue deterioration.	C
In patients with positive cytology, but negative cystoscopy, exclude a UTUC, CIS in the bladder (random biopsies or PDD targeted biopsies) and tumour in prostatic urethra (prostatic urethra biopsy).	C
If indicated, perform a second TURB within 2-6 weeks after initial resection. It should include resection of the primary tumour site.	C
Classification and pathological report	
Do not use the term "Superficial BC".	A
In difficult cases, consider an additional review by an experienced genitourinary pathologist.	B

CIS = carcinoma in situ; PDD = photodynamic diagnosis; TURB = transurethral resection of the bladder.

6.3.1 Recommendations for stratification of NMIBC

	GR
In patients treated with BCG, use CUETO risk tables for individual prediction of the risk of tumour recurrence and progression.	B

7.5 Recommendations for adjuvant therapy in Ta, T1 tumours and for therapy of CIS

	GR
In patients with intermediate-risk tumours, one immediate instillation of chemotherapy should be followed by 1-year full-dose BCG treatment, or by further instillations of chemotherapy for a maximum of 1 year. The final choice should reflect the individual patient's risk of recurrence and progression as well as the efficacy and side effects of each treatment modality.	A
In patients with high-risk tumours, full-dose intravesical BCG for 1-3 years is indicated. The additional beneficial effect of the second and third years of maintenance should be weighed against its added costs and inconvenience.	A
Intravesical chemotherapy	
Give clear instructions to the nursing staff to control the free flow of the bladder catheter at the end of the immediate instillation.	C

8.1 Guidelines for follow-up in patients after TURB of NMIBC

	GR
Consider R-biopsies or biopsies with PDD after intravesical treatment (at 3 or 6 months) in patients with CIS.	C

2. METHODS

2.1 Data Identification

For the current update, all articles published in 2014 and 2015 on NMIBC were considered. A systematic literature search for each section of the NMIBC Guidelines was performed by the Panel members. For identification of original and review articles, Medline, Web of Science, and Embase databases were used. These literature searches focused on identification of all level 1 scientific papers (randomized controlled trials [RCTs], systematic reviews [SRs], and meta-analyses of RCTs).

In this 2015 EAU Guidelines compilation, all standard information on levels of evidence (LE) and grading of recommendations (GR) has been taken out of the individual guidelines topics for the sake of brevity. This information is included in the introductory section of this print.

2.2 Review

This document was subjected to double-blind peer review prior to publication.

3. EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY

3.1 Epidemiology

Bladder cancer (BC) is the 11th most commonly diagnosed cancer in the world [4]. The worldwide age-standardised incidence rate (per 100,000 person-years) is 8.9 for men and 2.2 for women (2008 data) [4]. In the European Union (EU), the age-standardised incidence rate is 27 for men and six for women [4]. In Europe, the highest age-standardised incidence rate has been reported in Spain (41.5 in men and 4.8 in women) and the lowest in Finland (18.1 in men and 4.3 in women) [4].

Worldwide, BC is the 14th leading cause of cancer deaths, age-standardised mortality rate (per 100,000 person-years) was 3.3 for men versus 0.9 for women in 2008 [4]. In the EU, the age-standardised mortality rate was 8 for men and 3 for women, respectively [4].

BC incidence and mortality rates vary across the countries due to differences in risk factors, detection and diagnostic practices, and availability of treatments. The variations are however partly caused by the different methodology and quality of data collection [5, 6].

The incidence and mortality of BC has decreased in some registries, possibly reflecting the decreased impact of causative agents [6, 7].

Approximately 75% of patients with BC present with a disease confined to the mucosa (stage Ta, CIS) or submucosa (stage T1). They have a high prevalence due to long-term survival in many cases and lower risk of cancer specific mortality compared to T2-4 tumours [5, 8].

3.2 Aetiology

Tobacco smoking is the most important risk factor for BC, accounting for approximately 50% of cases [5, 9-11] (LE: 3). Tobacco smoke contains aromatic amines and polycyclic aromatic hydrocarbons, which are renally excreted.

Occupational exposure to aromatic amines, polycyclic aromatic hydrocarbons and chlorinated hydrocarbons is the second most important risk factor for BC, accounting for about 10% of all cases. This type of occupational exposure occurs mainly in industrial plants processing paint, dye, metal and petroleum products [5, 12-14]. In developed industrial settings, these risks have been reduced by work safety guidelines so that chemical workers no longer have a higher incidence of BC compared to the general population [15].

Genetic predisposition has an influence on the incidence of BC, especially via its impact on susceptibility to other risk factors [5, 16].

Although the significance of the amount of fluid intake is uncertain, the chlorination of drinking water and subsequent levels of trihalomethanes are potentially carcinogenic, while exposure to arsenic in drinking water increases risk [5, 8, 17] (LE: 3). The association between personal hair dye use and risk remains uncertain; an increased risk has been suggested in users of permanent hair dyes with an NAT2 slow acetylation phenotype [18, 19].

Exposure to ionizing radiation is connected with increased risk; weak association was also suggested for cyclophosphamide and pioglitazone [5, 8] (LE: 3). Schistosomiasis, a chronic endemic cystitis, based on recurrent infection with a parasitic trematode, is also a cause of BC [5] (LE: 3).

3.3 Pathology

The information presented in text is limited to urothelial carcinoma, unless specified otherwise.

4. STAGING AND CLASSIFICATION SYSTEMS

4.1 Definition of non-muscle-invasive bladder cancer

Papillary tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively, according to the Tumour, Node, Metastasis (TNM) classification system. Flat, high-grade tumours that are confined to the mucosa are classified as CIS (Tis). These tumours can be treated by transurethral resection of the bladder (TURB) and/or intravesical instillations and are therefore grouped under the heading of NMIBC for therapeutic purposes. However, molecular biology techniques and clinical experience have demonstrated the highly malignant potential of CIS and T1 lesions. The terms “NMIBC” and older one “superficial BC” are therefore suboptimal descriptions.

4.2 Tumour, Node, Metastasis Classification (TNM)

The 2002 TNM classification approved by the Union International Contre le Cancer (UICC) was updated in 2009 (7th version), but it had no changes for bladder tumours (Table 4.1) [20].

Table 4.1: 2009 TNM classification of urinary bladder cancer

T - Primary tumour	
TX	Primary tumour cannot be assessed
T0	No evidence of primary tumour
Ta	Non-invasive papillary carcinoma
Tis	Carcinoma <i>in situ</i> : 'flat tumour'
T1	Tumour invades subepithelial connective tissue Tumour invades muscle
T2	T2a Tumour invades superficial muscle (inner half) T2b Tumour invades deep muscle (outer half)
T3	Tumour invades perivesical tissue T3a Microscopically T3b Macroscopically (extravesical mass)
T4	Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall T4a Tumour invades prostate, uterus or vagina T4b Tumour invades pelvic wall or abdominal wall
N - Lymph nodes	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in a single lymph node in the true pelvis (hypogastric, obturator, external iliac, or presacral)
N2	Metastasis in multiple lymph nodes in the true pelvis (hypogastric, obturator, external iliac, or presacral)
N3	Metastasis in common iliac lymph node(s)
M - Distant metastasis	
MX	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastasis

4.3 Histological grading of non-muscle-invasive bladder urothelial carcinomas


In 2004, the World Health Organization (WHO) and the International Society of Urological Pathology (ISUP) published a new histological classification of urothelial carcinomas which provides a different patient stratification between individual categories compared to the older 1973 WHO classification [21, 22] (Tables 4.2, 4.3, Fig 4.1). A website (www.pathology.jhu.edu/bladder) that illustrates examples of the various grades has been developed to further improve accuracy in using the system.

Table 4.2: WHO grading in 1973 and in 2004 [21, 22]

<p>1973 WHO grading <i>Urothelial papilloma</i> Grade 1: well differentiated Grade 2: moderately differentiated Grade 3: poorly differentiated</p>
<p>2004 WHO grading system [papillary lesions] <i>Urothelial papilloma (completely benign lesion)</i> Papillary urothelial neoplasm of low malignant potential (PUNLMP) Low-grade (LG) papillary urothelial carcinoma High-grade (HG) papillary urothelial carcinoma</p>

The prognostic value of both WHO 1973 and 2004 grading systems has been confirmed. Attempts to demonstrate better prognostic value of one of them, however, have yielded controversial results [23-28] (LE: 2a). Moreover the WHO 2004 system has not been fully incorporated into prognostic models yet. Most clinical trials published to date on Ta, T1 bladder tumours have been performed using the 1973 WHO classification, and the following guidelines are therefore based on this version.

Figure 4.1: Stratification of tumours according to grade in the WHO 1973 and 2004 classifications [23]*



*1973 WHO Grade 1 carcinomas have been reassigned to papillary urothelial neoplasm of low malignant potential (PUNLMP) and low-grade (LG) carcinomas in 2004 WHO classification, and Grade 2 carcinomas to LG and high-grade (HG) carcinomas. All 1973 WHO Grade 3 carcinomas have been reassigned to HG carcinomas (Reproduced with permission from Elsevier).

PUNLMP = papillary urothelial neoplasm of low malignant potential; WHO = World Health Organization.

4.4 CIS and its classification

Carcinoma *in situ* (CIS) is a flat, high-grade, non-invasive urothelial carcinoma. It can be missed at cystoscopy or be considered as an inflammatory lesion if it is not biopsied. CIS is often multifocal and can occur in the bladder, but also in the upper urinary tract, prostatic ducts, and prostatic urethra [29].

Classification of CIS into clinical type [30]:

- Primary: isolated CIS with no previous or concurrent papillary tumours and no previous CIS;
- Secondary: CIS detected during follow-up of patients with a previous tumour that was not CIS;
- Concurrent: CIS in the presence of any other urothelial tumour in the bladder.

Table 4.3: WHO 2004 grading system

<p>WHO 2004 grading system (flat lesions):</p> <ul style="list-style-type: none"> • Hyperplasia (flat lesion without atypia or papillary aspects) • Reactive atypia (flat lesion with atypia) • Atypia of unknown significance • Urothelial dysplasia • Urothelial CIS is always high-grade
--

4.5 Inter- and intra-observer variability in staging and grading

There is significant variability among pathologists for diagnosis of CIS, for which agreement is achieved in only 70-78% of cases [31, 32] (LE: 2a). There is also interobserver variability in the classification of stage T1 versus Ta tumours and tumour grading in both 1997 and 2004 classifications. The general conformity in staging and grading is between 50% and 60% [27, 31-36] (LE: 2a). The published comparisons have not clearly confirmed that the WHO 2004 classification has better reproducibility than the 1973 classification [24, 27].

4.6 Further promising pathology parameters

Some novel parameters based on pathological investigation of resected tissue have been considered for subclassification and prognostic purposes.

In T1 tumours, the depth and extent of invasion into the lamina propria (T1 substaging) can be evaluated. The prognostic value of this evaluation has been demonstrated by some retrospective cohort studies [37-40] (LE: 3); nevertheless, it is not recommended in the WHO classification.

According to a meta-analysis of retrospective trials, the presence of lymphovascular invasion (LVI) in TURB specimens was connected with increased risk of pathological upstaging [41] (LE: 3). Lymphovascular invasion has been reported as an unfavourable prognostic factor in T1 tumours [42] (LE: 3).

Some variants of urothelial carcinoma (micropapillary, plasmocytoid, nested, sarcomatoid, squamous and adeno variants of urothelial carcinoma etc.), have a poor prognosis [43-47] (LE: 3).

Molecular markers, particularly FGFR3 mutation status, are promising but need further evaluation [25, 40, 48-50].

4.7 Recommendations

The recommendations for BC classification can be found in section 5.14.

5. DIAGNOSIS

5.1 Patient history

A comprehensive patient history is mandatory.

5.2 Signs and symptoms

Haematuria is the most common finding in NMIBC. Ta, T1 tumours do not cause bladder pain and rarely present with lower urinary tract symptoms. CIS might be suspected in patients who do complain of these symptoms, particularly if they are refractory to symptomatic treatment.

5.3 Physical examination

Physical examination does not reveal NMIBC.

5.4 Imaging

5.4.1 Computed tomography urography and intravenous urography

Computed tomography (CT) urography is used to detect papillary tumours in the urinary tract, which can be seen as filling defects or indicated by hydronephrosis.

Intravenous urography (IVU) can be an alternative if CT is not available [51] (LE: 3), but particularly in muscle-invasive tumours of the bladder and in UTUCs, CT urography gives more information than IVU does (including status of lymph nodes and neighbouring organs).

The necessity to perform a baseline CT urography or IVU once a bladder tumour has been detected is questioned because of the low incidence of significant findings obtained [52-54] (LE: 2a). The incidence of UTUCs is low (1.8%), but increases to 7.5% in tumours located in the trigone [53] (LE: 2b). The risk of UTUC during follow-up increases in patients with multiple- and high-risk tumours [55] (LE: 3).

5.4.2 Ultrasound (US)

Transabdominal US permits characterization of renal masses, detection of hydronephrosis, and visualization of intraluminal masses in the bladder. It is as accurate as IVU for diagnosis of UTUC [52] (LE: 3). Ultrasound is therefore a useful tool for detection of obstruction in patients with haematuria. However, it cannot exclude the presence of UTUC and cannot replace CT urography.

The diagnosis of CIS cannot be made with imaging methods (CT urography, IVU or US) (LE: 4).

5.5 Urinary cytology

The examination of voided urine or bladder-washing specimens for exfoliated cancer cells has high sensitivity in G3 tumours, but low sensitivity in G1 tumours. The sensitivity in CIS detection is 28-100% [56] (LE: 2b). Cytology is useful, particularly as an adjunct to cystoscopy, when a G3 malignancy or CIS is present. Positive voided urinary cytology can indicate an urothelial tumour anywhere in the urinary tract; negative cytology, however, does not exclude the presence of a tumour.

Cytological interpretation is user-dependent [57]. Evaluation can be hampered by low cellular yield, urinary tract infections, stones, or intravesical instillations, but in experienced hands specificity exceeds 90% [58] (LE: 2b). Urine collection should respect recommendations (see Section 5.9). One cytospin slide from the sample is usually sufficient [59]. In patients with suspect cytology it is reasonable to repeat the investigation [60] (LE: 3).

5.6 Urinary molecular marker tests

Driven by the low sensitivity of urine cytology, numerous urinary tests were developed [58, 61-68]. None of these markers have been accepted for diagnosis or follow-up in routine urology or in guidelines. Some urine tests that have been evaluated in several laboratories/centres and with sufficient numbers of patients are listed in Table 5.1.

The following conclusions can be drawn regarding the existing tests.

- Sensitivity is usually higher and at the cost of lower specificity compared to urine cytology [58, 62-72] (LE: 3).
- Benign conditions and BCG influence many urinary marker tests [58, 61-68] (LE: 3).
- Sensitivity and specificity of a urinary marker test depend on the clinical context of the patient

- (screening, primary detection, follow-up [high risk, low-/intermediate-risk]) [62-65] (LE: 3).
- Patient selection explains the wide range in performance of the markers listed in Table 5.1.
- Unlike other urine tests, false-positive results of UroVysion and microsatellite analysis can be attributed to occult disease and thus identify patients likely to experience early recurrence [73-77] (LE: 3).

Table 5.1: Summary of main urinary markers

Markers (or test specifications)	Overall sensitivity (%)	Overall specificity (%)	Sensitivity for high-grade tumours (%)	Point-of-care test	LE
UroVysion (FISH)	30-86	63-95	66-70	No	2b
Microsatellite analysis	58-92	73-100	90-92	No	1b
Immunocyt/uCyt +	52-100	63-79	62-92	No	2a
Nuclear matrix Protein 22	47-100	55-98	75-92	Yes	2a
BTA stat	29-83	56-86	62-91	Yes	3
BTA TRAK	53-91	28-83	74-77	No	3
Cytokeratins	12-88	73-95	33-100	No	3

BTA = bladder tumour antigen; LE = level of evidence.

5.7 Potential application of urinary cytology and markers

The following objectives of urinary cytology or molecular tests must be considered.

5.7.1 Screening of the population at risk of BC

The application of haematuria dipstick, NMP22 or UroVysion in BC screening in high-risk populations has been reported [78, 79]. The low incidence of BC in the general population and the short lead-time impair feasibility and cost-effectiveness [65, 77-79]. Routine application of screening is not recommended.

5.7.2 Exploration of patients after haematuria or other symptoms suggestive of BC (primary detection)

It is generally accepted that none of the tests can replace cystoscopy. However, urinary cytology or markers can be used as an adjunct to cystoscopy to detect invisible tumours, particularly CIS. In this setting, sensitivity for high-grade tumours and specificity are particularly important. Urinary cytology is highly specific, but urinary markers lack this high specificity and are not recommended for primary detection.

5.7.3 Surveillance of NMIBC

Research has been carried out into the usefulness of urinary cytology versus markers in the follow-up of NMIBC [65, 67, 80, 81].

5.7.3.1 Follow-up of high-risk NMIBC

High-risk tumours should be detected early in follow-up, and the percentage of tumours missed should be as low as possible. Therefore, the best surveillance strategy for these patients will continue to include frequent cystoscopy and cytology.

5.7.3.2 Follow-up of low-/intermediate-risk NMIBC

To reduce the number of cystoscopy procedures, urinary markers should be able to detect recurrence before the tumours are large and numerous. The limitation of urinary cytology is its low sensitivity for low-grade recurrences. Several urinary markers are better, but still do not detect half of the low-grade tumours identified by cystoscopy [62, 65] (LE: 3).

According to current knowledge, no urinary marker can replace cystoscopy during follow-up or help to lower cystoscopic frequency in a routine fashion. One prospective randomized study confirmed that knowledge of positive test results (microsatellite analysis) can improve the quality of follow-up cystoscopy [82] (LE: 1b). It supports the adjunctive role of a non-invasive urine test performed before follow-up cystoscopy [82].


5.8 Cystoscopy

The diagnosis of papillary BC ultimately depends on cystoscopic examination of the bladder and histological evaluation of the resected tissue. CIS is diagnosed by a combination of cystoscopy, urine cytology, and

histological evaluation of multiple bladder biopsies [83].

Cystoscopy is initially performed in the office. A flexible instrument with topical intra-urethral anaesthetic lubricant instillation results in better compliance compared to a rigid instrument, especially in men [84].

Figure 5.1: Bladder diagram



- | | |
|----------------------------|------------------------|
| 1 = Trigone | 6 = Anterior wall |
| 2 = Right ureteral orifice | 7 = Posterior wall |
| 3 = Left ureteral orifice | 8 = Dome |
| 4 = Right wall | 9 = Neck |
| 5 = Left wall | 10 = Posterior urethra |

5.9 Guidelines for the primary assessment of NMIBC

	GR
Patient history should be taken.	A
Renal and bladder US may be used during the initial work-up in patients with haematuria.	C
At the time of the initial diagnosis of NMIBC, CT urography (or IVU) should be performed only in selected cases (e.g., tumours located in the trigone, multiple- or high-risk tumours).	B
Cystoscopy is recommended in all patients with symptoms suggestive of BC. It cannot be replaced by cytology or by any other non-invasive test.	A
Cystoscopy should describe all macroscopic features of the tumour (site, size, number and appearance) and mucosal abnormalities. A bladder diagram is recommended (Figure 5.1).	C
Voided urine cytology is advocated to predict high-grade tumour before TURB.	C
Cytology should be performed on fresh urine with adequate fixation. Morning urine is not suitable because of the frequent presence of cytolysis.	C

BC = bladder cancer; CT = computed tomography; GR = grade of recommendation; IVU = intravenous urography; US = ultrasound; NMIBC = non-muscle invasive bladder cancer; TURB = transurethral resection of the bladder.

5.10 Transurethral resection of Ta, T1 bladder tumours

5.10.1 Strategy of the procedure

The goal of TURB in Ta,T1 BC is to make the correct diagnosis and completely remove all visible lesions. It is a crucial procedure in the diagnosis and treatment of BC. TURB should be performed systematically in individual steps (see Section 5.14). The strategy of resection depends on the size of the lesion (see Section 5.14). Separate resection of larger tumours provides good information about the vertical and horizontal extent of the tumour and helps to improve resection completeness [85, 86] (LE: 3).

Complete and correct TURB is essential to achieve a good prognosis [87]. It has been confirmed that the absence of detrusor muscle in the specimen is associated with a significantly higher risk of residual disease, early recurrence and tumour understaging [86, 88] (LE: 2b). It has been shown that surgical experience can improve TURB results, which supports the role of teaching programmes [89].

5.10.2 **Office-based fulguration**

In patients with a history of small, Ta LG/G1 tumours, fulguration of small papillary recurrences on an outpatient basis can reduce the therapeutic burden and can be a treatment option [90] (LE: 3).

5.10.3 **New resection techniques**

Compared to monopolar resection, the bipolar electrocautery system has been introduced to reduce the risk of complications (e.g., bladder perforation due to obturator nerve stimulation) and produce better specimens for the pathologist [91] (LE: 3). As yet, the results are controversial [92-94].

5.10.4 **Bladder and prostatic urethral biopsies**

Carcinoma *in situ* can present as a velvet-like, reddish area indistinguishable from inflammation, or it may not be visible at all. For this reason, the strategy of biopsies from abnormal urothelium and biopsies from normal-looking mucosa (random/mapping biopsies) was recommended (see Section 5.14). The indication of random biopsies reflects the fact, that the likelihood of detecting CIS, especially in low-risk tumours, is extremely low (< 2%) [95] (LE: 2a). The risk increases in patients with high-risk tumours and with positive cytology [96].

If equipment is available, photodynamic diagnosis (PDD) is a useful tool to target the biopsy (see Section 5.11.1).

Involvement of the prostatic urethra and ducts in men with NMIBC has been reported. Palou et al. [97] showed that in 128 men with T1G3 BC, the incidence of CIS in the prostatic urethra was 11.7% (LE: 2b). The risk of prostatic urethra- or duct involvement is higher if the tumour is located on the trigone or bladder neck, in the presence of bladder CIS and multiple tumours [98] (LE: 3). Based on this observation a biopsy from the prostatic urethra is necessary in some cases. A recommendation is included in Section 5.14 [97, 99].

5.11 **New methods of tumour visualization**

As a standard procedure, cystoscopy and TURB are performed using white light. However, the use of white light can lead to missing lesions that are present but not visible, which is why new technologies are being developed.

5.11.1 **Photodynamic diagnosis (fluorescence cystoscopy)**

Photodynamic diagnosis (PDD) is performed using violet light after intravesical instillation of 5-aminolaevulinic acid (ALA) or hexaminolaevulinic acid (HAL). It has been confirmed that fluorescence-guided biopsy and resection are more sensitive than conventional procedures for detection of malignant tumours, particularly for CIS [100, 101] (LE: 2a). In a systematic review and meta-analysis, PDD had higher sensitivity than white-light endoscopy in the pooled estimates for analyses at both the patient-level (92% versus 71%) and biopsy-level (93% versus 65%) [101].

PDD had lower specificity than white-light endoscopy (63% vs. 81%) [101]. False-positivity can be induced by inflammation or recent TURB and during the first 3 months after BCG instillation [102, 103] (LE: 3). Prospective randomized studies evaluating the impact of ALA fluorescence-guided (FC) TURB on disease recurrence rate provided controversial results [101, 104, 105].

The beneficial effect of HAL FC on recurrence rate in patients with TURB was confirmed by a multicentre, prospective, randomized trial and by raw-data based meta-analysis of controlled trials. A meta-analysis reported in HAL arms an increase in detection of tumour lesions across all risk groups and an absolute reduction of < 10% in recurrence rates within 12 months [106] (LE: 1a). The beneficial effect of HAL FC on recurrence rate in patients with TURB and early intravesical instillation of chemotherapy was not confirmed by a prospective randomized trial [107]. The value of FC for improvement of outcome in relation to progression rate, survival and clinical management remains to be demonstrated.

5.11.2 **Narrow-band imaging**

In narrow-band imaging (NBI), the contrast between normal urothelium and hyper-vascular cancer tissue is enhanced. Initial studies have demonstrated improved cancer detection by NBI-guided biopsies and resection [108, 109] (LE: 3). The suggested reduction of recurrence rate if NBI is used during TURB has not been fully confirmed yet [110].

5.12 **Second resection**

The significant risk of residual tumour after initial TURB of Ta, T1 lesions has been demonstrated [87] (LE: 2a).

Persistent disease after resection of T1 tumours has been observed in 33-55% of patients, and after resection of TaG3 tumour in 41.4% [111-115].

Moreover, the tumour is often understaged by initial resection. The likelihood that muscle-invasive disease is detected by second resection of initially T1 tumour ranges from 4-25%, and it increases to 45% if there was no muscle in the initial resection [86]. This risk has increased up to 50% in some radical cystectomy (RC) series, although these studies only enrolled selected patients [116-118] (LE: 2a). Treatment of a Ta, T1 high-grade tumour and a T2 tumour is completely different; correct staging is therefore important.

It has been demonstrated that a second TURB can increase recurrence-free survival [111, 112] (LE: 2a), improve outcomes after BCG treatment [119] (LE: 3) and provide prognostic information [116, 120] (LE: 3)

Based on these arguments, a second TURB is recommended in selected cases (see Section 5.14).

5.13 Pathology report

Pathology investigation of the specimen obtained by TURB and biopsies is an essential step in the diagnosis and treatment decision-making process for BC. Close co-operation between urologists and pathologists is recommended.

A high quality of resected and submitted tissue is essential for correct pathological assessment. The presence of sufficient muscle is necessary for the correct assignment of T category. To achieve all required information, the specimen collection, handling and evaluation should respect the recommendations provided below (section 5.14) [121].

5.14 Guidelines for TURB and/or biopsies, tumour classification and pathology report

	GR
Perform TURB systematically in individual steps: <ul style="list-style-type: none"> • bimanual palpation under anaesthesia; • insertion of the resectoscope, under visual control with inspection of the whole urethra; • inspection of the whole urothelial lining of the bladder; • biopsy from prostatic urethra (if indicated); • cold-cup bladder biopsies (if indicated); • resection of the tumour; • surgical report formulation; • precise description of the specimen for pathology evaluation. 	C
Performance of individual steps:	
Perform resection in one piece for small papillary tumours (< 1 cm), including a part from the underlying bladder wall.	B
Perform resection in fractions including the exophytic part of the tumour, the underlying bladder wall with the detrusor muscle, and the edges of the resection area for tumours > 1 cm in diameter.	B
Avoid cauterization as much as possible during TURB to avoid tissue deterioration.	C
Take biopsies from abnormal-looking urothelium.	
Biopsies from normal-looking mucosa (trigone, bladder dome, and right, left, anterior and posterior bladder walls) are recommended when cytology is positive or when high-risk exophytic tumour is expected (non-papillary appearance).	C
Take biopsy of the prostatic urethra in cases of bladder neck tumour, when bladder CIS is present or suspected, when there is positive cytology without evidence of tumour in the bladder, or when abnormalities of the prostatic urethra are visible. If biopsy is not performed during the initial procedure, it should be completed at the time of the second resection.	C
Take the biopsy from abnormal areas in the prostatic urethra and from the precollicular area (between the 5 and 7 o'clock position) using a resection loop. In primary non-muscle-invasive tumours when stromal invasion is not suspected, the cold-cup biopsy with forceps can be used.	C
If equipment is available, use fluorescence-guided (PDD) biopsy instead of random biopsies when bladder CIS or high-grade tumour is suspected (e.g., positive cytology, recurrent tumour with previous history of a high-grade lesion).	B
Refer the specimens from different biopsies and resection fractions to the pathologist in separate containers and label them separately.	C
TURB protocol must describe tumour appearance, all steps of the procedure, as well as the extent and completeness of resection.	C
In patients with positive cytology, but negative cystoscopy, exclude a UTUC, CIS in the bladder (random biopsies or PDD targeted biopsies) and tumour in the prostatic urethra (prostatic urethra biopsy).	C

Perform a second TURB in the following situations: <ul style="list-style-type: none"> • after incomplete initial TURB; • if there is no muscle in the specimen after initial resection, with the exception of TaG1 tumours and primary CIS; • in all T1 tumours; • in all G3 tumours, except primary CIS. 	A
If indicated, perform a second TURB within 2-6 weeks after initial resection. It should include resection of the primary tumour site.	C
Classification and pathological report	
For classification of the depth of tumour invasion (staging) use the 2009 TNM system.	A
For histological classification, use both the 1973 and 2004 WHO grading.	A
Do not use the term "Superficial BC".	A
Whenever using the terminology NMIBC, in individual cases, mention the tumour stage and grade.	A
The pathological report should specify tumour location, tumour grade, depth of tumour invasion, presence of CIS, and whether the detrusor muscle is present in the specimen.	A
The pathological report should specify the presence of LVI or unusual (variant) histology.	C
In difficult cases, consider an additional review by an experienced genitourinary pathologist.	B

BC = bladder cancer; CIS = carcinoma in situ; CT = computed tomography; LVI = lymphovascular invasion; PDD = photodynamic diagnosis; TNM = Tumour, Node, Metastasis; TURB = transurethral resection of the bladder; WHO = World Health Organisation.

6. PREDICTING DISEASE RECURRENCE AND PROGRESSION

6.1 Ta, T1 tumours

In order to predict separately the short- and long-term risks of disease recurrence and progression in individual patients, the European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Cancer Group (GUCG) has developed a scoring system and risk tables [122]. The basis for these tables are individual patient data for 2,596 patients diagnosed with Ta, T1 tumours, who were randomized into seven EORTC-GUCG trials. Patients with CIS alone were not included. Seventy-eight percent of patients received intravesical treatment, mostly chemotherapy. However, they did not undergo a second TURB or receive maintenance BCG.

The scoring system is based on the six most significant clinical and pathological factors which are shown in Table 6.1.

It also illustrates the weights applied to various factors for calculating the total scores for recurrence and progression. Table 6.2 shows the total scores stratified, as in the original article [122], into four categories that reflect various probabilities of recurrence and progression at 1 and 5 years (LE: 2a).

Table 6.1: Weighting used to calculate disease recurrence and progression scores

Factor	Recurrence	Progression
Number of tumours		
Single	0	0
2-7	3	3
≥ 8	6	3
Tumour diameter		
< 3 cm	0	0
≥ 3	3	3
Prior recurrence rate		
Primary	0	0
≤ 1 recurrence/year	2	2
> 1 recurrence/year	4	2
Category		
Ta	0	0
T1	1	4
Concurrent CIS		
No	0	0
Yes	1	6
Grade		
G1	0	0
G2	1	0
G3	2	5
Total Score	0-17	0-23

Table 6.2: Probability of recurrence and disease progression according to total score

Recurrence score	Probability of recurrence at 1 year		Probability of recurrence at 5 years	
	%	(95% CI)	%	(95% CI)
0	15	(10-19)	31	(24-37)
1-4	24	(21-26)	46	(42-49)
5-9	38	(35-41)	62	(58-65)
10-17	61	(55-67)	78	(73-84)

Progression score	Probability of progression at 1 year		Probability of progression at 5 years	
	%	(95% CI)	%	(95% CI)
0	0.2	(0-0.7)	0.8	(0-1.7)
2-6	1	(0.4-1.6)	6	(5-8)
7-13	5	(4-7)	17	(14-20)
14-23	17	(10-24)	45	(35-55)

NB: Electronic calculators for Tables 6.1 and 6.2, which have been updated for the iPhone, iPad and Android phones and tablets, are available at <http://www.eortc.be/tools/bladdercalculator/>.

A scoring model for BCG-treated patients that predicts the short- and long-term risks of recurrence and progression has been published by the Club Urológico Español de Tratamiento Oncológico (CUETO) (Spanish Urological Oncology Group). It is based on an analysis of 1,062 patients from four CUETO trials that compared different intravesical BCG treatments. Patients received 12 instillations over 5-6 months. No immediate postoperative instillation or second TURB was performed in these patients. The scoring system is based on the evaluation of seven prognostic factors:

- sex;
- age;
- prior recurrence status;
- number of tumours;
- T category;
- associated CIS;
- tumour grade.

Using these tables, the calculated risk of recurrence is lower than that obtained by the EORTC tables. For progression, probability is lower only in high-risk patients [123] (LE: 2a). The lower risks in the CUETO tables may be attributed to using BCG, which is a more effective instillation therapy. The CUETO risk calculator is available at: <http://www.aeu.es/Cueto.html>.

The prognostic value of the EORTC scoring system has been confirmed by data from the CUETO patients treated with BCG and by long-term follow-up in an independent patient population [124, 125] (LE: 2a).

Further prognostic factors have been described in selected patient populations:

- In T1G3 tumours important prognostic factors were female sex and CIS in the prostatic urethra in patients treated with an induction course of BCG, and age, tumour size and concurrent CIS in BCG treated patients (62% with induction course only) [97, 126] (LE: 2b).
- Attention must be given to patients with T1G3 tumours in bladder (pseudo) diverticulum because of an absence of muscle layer in the diverticular wall [127] (LE: 3).
- In patients with high-risk disease, the tumour stage at the time of the 2nd TURB is an unfavourable prognostic factor [116, 120] (LE: 3)
- In patients with T1G2 tumours treated with TURB, recurrence at 3 months was the most important predictor of progression [128] (LE: 2b).
- The prognostic value of pathological factors has been discussed elsewhere (see Section 4.6). More research is needed to determine the role of molecular markers in improving the predictive accuracy of currently existing risk tables [124, 129].

6.2 Carcinoma *in situ*

Without any treatment, approximately 54% of patients with CIS progress to muscle-invasive disease [130] (LE: 3). Unfortunately, there are no reliable prognostic factors that can be used to predict the course of the disease. Publications are based on retrospective analyses of small series of patients and conclusions are not homogeneous. Some studies have reported a worse prognosis in concurrent CIS and T1 tumours compared to primary CIS [131, 132], in extended CIS [133], and in CIS in the prostatic urethra [97] (LE: 3).

The response to intravesical treatment with BCG or chemotherapy is an important prognostic factor for subsequent progression and death caused by BC [123-125, 128]. Approximately 10-20% of complete responders eventually progress to muscle-invasive disease, compared with 66% of non-responders [134, 135] (LE: 2a).

6.3 Patients' stratification into risk groups

To facilitate treatment recommendations it is important to categorise patients into risk groups. Based on available prognostic factors and in particular data from the EORTC risk tables, the Guidelines Panel recommends stratification of patients into three risk groups. Table 6.3 provides a definition of these risk groups, which takes into account the EORTC risk tables' probabilities of recurrence and especially progression.

Table 6.3: Risk group stratification

Risk group stratification	Characteristics
Low-risk tumours	Primary, solitary, Ta, G1* (PUNLMP, LG), < 3 cm, no CIS
Intermediate-risk tumours	All tumours not defined in the two adjacent categories (between the category of low- and high-risk).
High-risk tumours	Any of the following: <ul style="list-style-type: none"> • T1 tumour • G3** (HG) tumour • CIS • Multiple and recurrent and large (> 3 cm) Ta G1G2 tumours (all conditions must be presented in this point)*

Substratification of high-risk tumours for clinical purposes can be seen in Table 7.2.

*low grade is a mixture of G1 and G2

** high grade is a mixture of some G2 and all G3 (see Figure 4.1)

CIS = carcinoma *in situ*; HG = high-grade; LG = low-grade.

6.3.1 Recommendations for stratification of NMIBC

	GR
Stratify patients into three risk groups according to Table 6.2.	B
Apply the EORTC risk tables and calculator for individual prediction of the risk of tumour recurrence and progression in different intervals after TURB.	B
In patients treated with BCG, use the CUETO risk tables for individual prediction of the risk of tumour recurrence and progression.	B

BCG = *Bacillus Calmette-Guérin*; CUETO = *Club Urológico Español de Tratamiento Oncológico*; GR = *grade of recommendation*; EORTC = *European Organization for Research and Treatment of Cancer*; TURB = *transurethral resection of the bladder*.

7. DISEASE MANAGEMENT

7.1 Counselling of smoking cessation

It has been confirmed that smoking increases the risk of tumour recurrence and progression [136, 137] (LE: 3).

While it is still controversial whether smoking cessation in bladder cancer will favourably influence the outcome of BC treatment, patients should be counselled to stop smoking due to the general risks connected with tobacco smoking [138-140, 141] (LE: 3).

7.2 Adjuvant treatment

7.2.1 Intravesical chemotherapy

Although TURB by itself can eradicate a Ta, T1 tumour completely, these tumours commonly recur and can progress to MIBC. The high variability in the 3-month recurrence rate indicates that the TURB was incomplete or provokes recurrences in a high percentage of patients [87]. It is therefore necessary to consider adjuvant therapy in all patients.

7.2.1.1 A single, immediate, post-operative intravesical instillation of chemotherapy

Immediate single instillation (SI) has been shown to act by the destruction of circulating tumour cells resulting from TURB, and by an ablative effect (chemoresection) on residual tumour cells at the resection site and on small overlooked tumours [142-145] (LE: 3).

Three large meta-analyses comprising 1,476 to 3,103 patients have consistently shown that SI after TURB significantly reduced the recurrence rate by 11.7% to 13.0% compared to TURB alone [146-148] (LE: 1a). Although none of the three meta-analyses adequately answered the question concerning which patients benefitted the most, some underpowered data from two subgroup analyses [149, 150] suggest that SI is most effective in tumour types with the lowest tendency towards recurrence, i.e., in single primary or small tumours. Mitomycin C (MMC), epirubicin, and doxorubicin have all shown a beneficial effect; no efficacy comparisons have been made [146-148] (LE: 1a).

There is evidence from one subgroup- and one combined analysis that SI might have an impact on recurrence, even when further adjuvant instillations are given [151-153] (LE: 2a). In contrast, a sufficient number of delayed repeat chemotherapy instillations can also reduce recurrence stemming from tumour implantation [151-154]. Clearly, more studies comparing immediate and delayed-start regimens are needed.

The prevention of tumour cell implantation should be initiated within the first hours after cell seeding. Within a few hours, the cells are implanted firmly and are covered by extracellular matrix [142, 155-157] (LE: 3). In all SI studies, the instillation was administered within 24 hours. To maximize the efficacy of SI, one should devise flexible practices that allow the instillation to be given as early as possible, which is in the recovery room or even in the operating theatre.

As severe complications have been reported in patients with drug extravasation [158, 159], safety measures should be maintained (see Section 7.5).

7.2.1.2 Additional adjuvant intravesical chemotherapy instillations

The need for further adjuvant intravesical therapy depends on prognosis. In low-risk patients (Tables 6.1, 6.2 and 6.3), a SI reduces the risk of recurrence and is considered to be the standard and sufficient treatment [146] (LE: 1a). For other patients, however, a SI remains an incomplete treatment because of the considerable likelihood of recurrence and/or progression (Tables 6.1, 6.2 and 6.3). It was shown that further chemotherapy instillations can improve RFS in intermediate-risk tumours [154].

A large meta-analysis of 3,703 patients from 11 randomized trials showed a highly significant

44% reduction in the odds of recurrence at one year in favour of chemotherapy over TURB alone [160]. This corresponds to an absolute difference of 13-14% in the number of patients with recurrence. Contrary to chemotherapy, two meta-analyses have demonstrated that BCG therapy may reduce the risk of tumour progression [161, 162] (LE: 1a) (see Section 8.2.1). Moreover, BCG maintenance therapy appears to be significantly better in preventing recurrences than chemotherapy [163-165] (see Section 7.2.2) (LE: 1a). However, BCG causes significantly more side effects than does chemotherapy [165] (LE: 1a).

The length and frequency of chemotherapy instillations is still controversial. A systematic review of RCTs, comparing different schedules of intravesical chemotherapy instillations, concluded that the ideal duration and intensity of the schedule remains undefined because of conflicting data [153]. The available evidence does not support treatment longer than one year (LE: 3).

7.2.1.3 *Options for improving efficacy of intravesical chemotherapy*

Some promising data have been presented on enhancing the efficacy of MMC using microwave-induced hyperthermia or electromotive drug administration (EMDA) in patients with high-risk tumours. The current evidence, however, is limited [166, 167] and both treatment modalities are considered to be experimental (LE: 2b).

One RCT using MMC has demonstrated that adapting urinary pH, decreasing urinary excretion, and buffering the intravesical solution reduced the recurrence rate [168] (LE: 1b). Another trial reported that a 1-hour instillation of MMC was more effective than 30 minutes instillation, but no efficacy comparisons are available for 1- and 2-hour instillations [169] (LE: 3). Another RCT using epirubicin has documented that concentration is more important than treatment duration [170] (LE: 1b). In view of these data, instructions are provided (see Section 7.5)

7.2.2 ***Intravesical bacillus Calmette-Guérin (BCG) immunotherapy***

7.2.2.1 *Efficacy of BCG*

Five meta-analyses have confirmed that BCG after TURB is superior to TURB alone or TURB + chemotherapy for preventing the recurrence of NMIBC [163, 171-174] (LE: 1a). Three recent RCTs of intermediate- and high-risk tumours have compared BCG with epirubicin + interferon [175], MMC [176], or epirubicin alone [164] and have confirmed the superiority of BCG for prevention of tumour recurrence (LE: 1a). The effect is long-lasting [164, 176] and was also observed in a separate analysis of patients with intermediate-risk tumours [164].

One meta-analysis [163] has evaluated the individual data from 2,820 patients enrolled in nine RCTs that have compared MMC versus BCG. In the trials with BCG maintenance, there was a 32% reduction in the risk of recurrence for BCG compared to MMC, but a 28% increase in the risk of recurrence for patients treated with BCG in the trials without BCG maintenance.

Two meta-analyses have demonstrated that BCG therapy prevents, or at least delays, the risk of tumour progression [161, 162] (LE: 1a). A meta-analysis carried out by the EORTC-GUCG has evaluated data from 4,863 patients enrolled in 24 RCTs. Five different BCG strains were used, and in 20 of the trials, some form of BCG maintenance was used. Based on a median follow-up of 2.5 years, in 260 out of 2,658 patients (9.8%) treated with BCG, tumours progressed compared to 304 out of 2,205 (13.8%) in the control groups (TURB alone, TURB + intravesical chemotherapy, or TURB + other immunotherapy). This shows a reduction of 27% in the odds of progression with BCG maintenance treatment. The size of the reduction was similar in patients with Ta, T1 papillary tumours and in those with CIS [162]. A recent RCT with long-term observation has demonstrated significantly fewer distant metastases and better overall- and disease-specific survival in patients treated with BCG compared to epirubicin [164] (LE: 1b). On the contrary, a meta-analysis of individual patient data was not able to confirm any statistically significant difference between MMC and BCG for progression, survival and cause of death [163].

The conflicting results in the outcomes of these studies can be explained by different patient characteristics, duration of follow-up, methodology and statistical power. However, most studies showed a reduction in the risk of progression in high- and intermediate-risk tumours if BCG was applied including a maintenance schedule.

Two other meta-analyses have suggested a possible bias in favour of BCG arising from the inclusion of patients previously treated with intravesical chemotherapy [177]. In the most recent meta-analysis, however, BCG maintenance was more effective than MMC both in patients previously treated and not previously treated with chemotherapy [163] (LE: 1a).

It was demonstrated that BCG was less effective in patients > 70 years of age, but it was still more effective than epirubicin [178] (LE: 1a).

According to a published meta-analysis of 4 RCTs, the addition of chemotherapy to maintenance BCG does not improve the efficacy [179]. One smaller RCT demonstrated promising results of the addition of electromotive administered MMC to BCG, however, this requires further confirmation [167].

7.2.2.2 BCG strain

The EORTC meta-analysis suggested no large differences in efficacy between various BCG strains [162]. Recently published smaller studies without maintenance demonstrated some differences between strains. This clearly needs further evaluation in prospective trials [180, 181] (LE: 2a).

7.2.2.3 BCG toxicity

BCG intravesical treatment is associated with more side effects compared to intravesical chemotherapy [162] (LE: 1a). However, serious side effects are encountered in < 5% of patients and can be treated effectively in almost all cases [182] (LE: 1b). It has been shown that a maintenance schedule is not associated with an increased risk of side effects compared to an induction course [182]. Side effects requiring treatment stoppage were seen more often in the first year of therapy [183].

Major complications can appear after systemic absorption of the drug. Thus, contraindications of BCG intravesical instillation should be respected (see Section 7.5).

The presence of leukocyturia, non-visible haematuria or asymptomatic bacteriuria is not a contraindication for BCG application, and antibiotic prophylaxis is not necessary in these cases [184, 185] (LE: 3).

BCG should be used with caution (relative contraindication) in immunocompromised patients (immunosuppression, human immunodeficiency virus [HIV] infection) [186], although some small studies have shown similar efficacy and no increase in complications compared to non-immunocompromised patients [187, 188] (LE: 3).

The management of side effects after BCG should reflect their type and grade according the recommendations provided by the International Bladder Cancer Group (IBCG) and by a Spanish group [189, 190] (Table 7.1).

Table 7.1: Management options for side effects associated with intravesical BCG [190-193]

Management options for local side effects (modified from the IBCG group)	
Symptoms of cystitis	Phenazopyridine, propantheline bromide, or NSAIDs.
	If symptoms improve within a few days: continue instillations.
	If symptoms persist or worsen: <ol style="list-style-type: none"> a. Postpone the instillation; b. Perform a urine culture; c. Start empirical antibiotic treatment.
	If symptoms persist even with antibiotic treatment: <ol style="list-style-type: none"> d. With positive culture: antibiotic treatment according to sensitivity e. With negative culture: quinolones and potentially analgesic anti-inflammatory instillations once daily for 5 days (repeat cycle if necessary) [191].
	If symptoms persist: anti-tuberculosis drugs + corticosteroids.
	If no response to treatment and/or contracted bladder: radical cystectomy.
Haematuria	Perform urine culture to exclude haemorrhagic cystitis, if other symptoms present.
	If haematuria persists, perform cystoscopy to evaluate presence of bladder tumour.
Symptomatic granulomatous prostatitis	Symptoms rarely present: perform urine culture.
	Quinolones.
	If quinolones are not effective: isoniazid (300 mg/day) and rifampicin (600 mg/day) for 3 months.
	Cessation of intravesical therapy.
Epididymo-orchitis [192]	Perform urine culture and administer quinolones.
	Cessation of intravesical therapy.
	Orchidectomy if abscess or no response to treatment.

Management options for systemic side effects	
General malaise, fever	Generally resolve within 48 hours, with or without antipyretics.
Arthralgia and/or arthritis	Rare complication and considered autoimmune reaction.
	Arthralgia: treatment with NSAIDs.
	Arthritis: NSAIDs.
	If no/partial response, proceed to corticosteroids, high-dose quinolones or anti-tuberculosis drugs [193].
Persistent high-grade fever (> 38.5°C for > 48 h)	Permanent discontinuation of BCG instillations.
	Immediate evaluation: urine culture, blood tests, chest X-ray.
	Prompt treatment with > two antimicrobial agents while diagnostic evaluation is conducted.
	Consultation with an infectious diseases specialist.
BCG sepsis	Prevention: initiate BCG at least 2 weeks post-TURB (if no signs and symptoms of haematuria).
	Cessation of BCG.
	For severe infection: <ul style="list-style-type: none"> • High-dose quinolones or isoniazid, rifampicin and ethambutol 1.2 g daily for 6 months. • Early, high-dose corticosteroids as long as symptoms persist. Consider an empirical non-specific antibiotic to cover Gram-negative bacteria and/or Enterococcus.
Allergic reactions	Antihistamines and anti-inflammatory agents.
	Consider high-dose quinolones or isoniazid and rifampicin for persistent symptoms.
	Delay therapy until reactions resolve.

BCG = *bacillus Calmette-Guérin*; IBCG = *International Bladder Cancer Group*; NSAID = *non-steroidal anti-inflammatory drug*; TURBT = *transurethral resection of bladder tumour*.

7.2.2.4 Optimal BCG schedule

Induction BCG instillations are given according to the empirical 6-weekly schedule introduced by Morales in 1976 [194]. For optimal efficacy, BCG must be given in a maintenance schedule [161-163, 174] (LE: 1a). Many different maintenance schedules have been used, ranging from a total of 10 instillations given in 18 weeks to 27 over 3 years [195]. The EORTC meta-analysis was unable to determine which BCG maintenance schedule was the most effective [162]. In their meta-analysis, Böhle et al. concluded that at least one year of maintenance BCG is required to obtain superiority of BCG over MMC for prevention of recurrence or progression [161] (LE: 1a).

The optimal number of induction instillations and optimal frequency and duration of maintenance instillations remain unknown [196]. However, in a RCT of 1,355 patients, the EORTC has shown that when BCG is given at full dose, 3 years' maintenance reduces the recurrence rate compared to one year in high- but not in intermediate-risk patients. There were no differences in progression or overall survival. In the 3-year arm, however, 36.1% of patients did not complete the 3-years schedule [197] (LE: 1b). The benefit of the two additional years of maintenance in the high-risk patients should be weighed against its added costs and inconvenience.

7.2.2.5 Optimal dose of BCG

To reduce BCG toxicity, instillation of a reduced dose was proposed. However, it has been suggested that a full dose of BCG is more effective in multifocal tumours [198, 199] (LE: 1b). The CUETO study compared one-third dose to full-dose BCG and found no overall difference in efficacy. One-third of the standard dose of BCG might be the minimum effective dose for intermediate-risk tumours. A further reduction to one-sixth dose resulted in a decrease in efficacy with no decrease in toxicity [200] (LE: 1b).

The EORTC did not find any difference in toxicity between one-third and full-dose BCG, but one-third dose BCG was associated with a higher recurrence rate, especially when it was given only for one year [183, 197] (LE: 1b). Moreover, the routine application is complicated by potential technical difficulties in preparing the reduced dose reliably.

7.2.2.6 Indications for BCG

Although BCG is a very effective treatment, there is a consensus that not all patients with NMIBC should be treated with BCG due to the risk of toxicity. Ultimately, the choice of treatment depends upon the patient's risk (Table 6.2). The recommendation for individual risk groups is provided in Section 7.5.

7.2.3 **Specific aspects of treatment of CIS**

7.2.3.1 *Treatment strategy*

The detection of concurrent CIS increases the risk of recurrence and progression of Ta,T1 tumours [122, 123], further treatment according to the criteria summarized in Sections 7.2.1, 7.2.2, 7.3 and 7.4 is mandatory.

CIS cannot be cured by an endoscopic procedure alone. Histological diagnosis of CIS must be followed by further treatment, either intravesical BCG instillations or RC (LE: 4). Tumour-specific survival rates after immediate RC for CIS are excellent, but as many as 40-50% of patients might be over-treated [130] (LE: 3).

7.2.3.2 *Cohort studies on intravesical BCG or chemotherapy*

In retrospective evaluations of patients with CIS, a complete response rate of 48% was achieved with intravesical chemotherapy and 72-93% with BCG [130-133, 201] (LE: 2a). Up to 50% of complete responders might eventually show recurrence with a risk of invasion and/or extravesical recurrence [133, 195, 201, 202] (LE: 3).

7.2.3.3 *Prospective randomized trials on intravesical BCG or chemotherapy*

Unfortunately, there have been few randomized trials in patients with CIS alone. A meta-analysis of clinical trials comparing intravesical BCG to intravesical chemotherapy in patients with CIS has shown a significantly increased response rate after BCG and a reduction of 59% in the odds of treatment failure with BCG [203] (LE: 1a).

In an EORTC-GUCG meta-analysis of tumour progression (a subgroup of 403 patients with CIS), BCG reduced the risk of progression by 35% as compared to intravesical chemotherapy or different immunotherapy [162] (LE: 1b). The combination of BCG and MMC is not superior to BCG alone [204]. In summary, compared to chemotherapy, BCG treatment of CIS increases the complete response rate, the overall percentage of patients who remain disease free, and reduces the risk of tumour progression (LE: 1a).


7.2.3.4 *Treatment of extravesical CIS*

Patients with CIS are at high risk of extravesical involvement in the UUT and in the prostatic urethra. Solsona et al. found that 63% of 138 patients with CIS developed extravesical involvement initially or during follow-up [205]. Patients with extravesical involvement had worse survival than those with bladder CIS alone [205] (LE: 3).

In the prostate, CIS might be present only in the epithelial lining of the prostatic urethra or in the prostatic ducts [29]. These situations should be distinguished from tumour invasion into the prostatic stroma (stage T4a in bladder tumours), and for which immediate radical cystoprostatectomy is mandatory. Patients with CIS in the epithelial lining of the prostatic urethra can be treated by intravesical instillation of BCG. TUR of the prostate can improve contact of BCG with the prostatic urethra [84, 206] (LE: 3).

In patients with prostatic duct involvement, there are promising results after BCG instillation, but only from small series, so the data are insufficient to provide clear treatment recommendations and radical surgery should be considered [206, 207] (LE: 3). Treatment of CIS that involves the UUT is discussed in the Guidelines on Urothelial Tumours of the Upper Urinary Tract (UTUCs).

Flowchart 7.1: Treatment strategy in primary or recurrent tumour(s) without previous BCG*



*For details and explanations see the text of the guidelines

BCG = bacillus Calmette-Guérin; GR = grade of recommendation; MIBC = muscle-invasive bladder cancer; PDD = photodynamic diagnosis; TURB = transurethral resection of the bladder.

7.3 Treatment of failure of intravesical therapy

7.3.1 Failure of intravesical chemotherapy

Patients with non-muscle-invasive recurrence of BC after a chemotherapy regimen can benefit from BCG instillations. Prior intravesical chemotherapy has no impact on the effect of BCG instillation [163] (LE: 1a).

7.3.2 Recurrence and failure after intravesical BCG immunotherapy

Table 7.2: Categories of unsuccessful treatment with intravesical BCG

BCG failure
Whenever a MIBC is detected during follow-up.
BCG-refractory tumour: 1. If high-grade, non-muscle-invasive papillary tumour is present at 3 months [208]. Further conservative treatment with BCG is associated with increased risk of progression [134, 209] (LE: 3). 2. If CIS (without concomitant papillary tumour) is present at both 3 and 6 months. In patients with CIS present at 3 months, an additional BCG course can achieve a complete response in > 50% of cases [29] (LE: 3). 3. If high-grade tumour appears during BCG therapy*.
High-grade recurrence after BCG. Recurrence of high-grade/grade 3 (WHO 2004/1973) tumour after completion of BCG maintenance, despite an initial response [210] (LE: 3)*.
BCG intolerance
Severe side effects that prevent further BCG instillation before completing induction [190].

* Patients with low-grade recurrence during or after BCG treatment are not considered to be a BCG failure. BCG = bacillus Calmette-Guérin; CIS = carcinoma in situ; LE = level of evidence.

7.3.3 Treatment of BCG failure and recurrences after BCG

Treatment recommendations are provided in Table 7.4. They reflect categories mentioned in Table 7.2 and tumour characteristics at the time of recurrence.


Patients with BCG failure are unlikely to respond to further BCG therapy; RC is therefore the preferred option. Various studies suggest that repeat BCG therapy is appropriate for non-high grade and even for some high-grade recurrent tumours [211, 212] (LE: 3). Additionally, there are now several bladder preservation strategies available that can be categorized as immunotherapy, chemotherapy, device-assisted therapy, and combination therapy [213]. Changing from BCG to these options can yield responses in selected cases with BCG treatment failure [211, 214-221] (LE: 3).

Treatments other than RC must be considered oncologically inferior in patients with BCG failure at the present time [134, 208, 209] (LE: 3).

Little is known about the optimal treatment in patients with high-risk tumours who could not complete BCG instillations because of intolerance.

Non-high grade recurrence after BCG is not considered as BCG failure. Treatment decision should be individual according to the tumour characteristics. It could include chemotherapy or repeat BCG instillations, but the published evidence is very low.

Flowchart 7.2: Treatment strategy in recurrence during or after intravesical BCG*



*For details and explanations, see the text of the guidelines.

BCG = bacillus Calmette-Guérin; GR = grade of recommendation; IVU = intravenous urography; PDD = photodynamic diagnosis; TURB = transurethral resection of the bladder.

7.4 Radical cystectomy for NMIBC

If RC is indicated before progression to muscle-invasive tumour, it can be performed as an immediate (immediately after NMIBC diagnosis) or early (after BCG failure) procedure.

There are several reasons to consider immediate RC for selected patients with NMIBC:

- The staging accuracy for T1 tumours by TURB is low with 27-51% of patients being upstaged to muscle-invasive tumour at RC [99, 117, 222-227] (LE: 3).
- Some patients with NMIBC experience disease progression to muscle-invasive disease (Table 6.2).

The potential benefit of RC must be weighed against the risk, morbidity, and impact on quality of life. It is reasonable to propose immediate RC in those patients with NMIBC who are at highest risk of progression (see Table 7.3) [44, 97, 122, 123] (LE: 3).

The benefits and risks of immediate and delayed RC should be discussed with patients. Individual additional prognostic factors in T1 G3 tumours mentioned in Section 6.1, as well as pathologic parameters (particularly LVI and unusual histologies) mentioned in Section 4.6, should be considered.

Early RC is strongly recommended in patients with BCG-refractory tumours, as mentioned above. A delay in RC might lead to decreased disease-specific survival [228] (LE: 3). In patients in whom RC is performed at the time of pathological NMIBC, the 5-year disease-free survival rate exceeds 80% [229-233] (LE: 3).

Table 7.3: Treatment recommendations in Ta, T1 tumours and CIS according to risk stratification

Risk category	Definition	Treatment recommendation
Low-risk tumours	Primary, solitary, Ta, LG/G1, < 3 cm, no CIS	One immediate instillation of chemotherapy.
Intermediate-risk tumours	All cases between categories of low and high risk	One immediate instillation of chemotherapy followed by further instillations, either chemotherapy for a maximum of 1 year or 1-year full-dose BCG.
High-risk tumours	Any of the following: <ul style="list-style-type: none"> • T1 tumours; • HG/G3 tumours; • CIS; • Multiple and recurrent and large (> 3 cm) Ta G1G2 tumours (all these conditions must be present). 	Intravesical full-dose BCG instillations for 1-3 years or cystectomy (in highest-risk tumours).
Subgroup of highest-risk tumours	T1G3 associated with concurrent bladder CIS, multiple and/or large T1G3 and/or recurrent T1G3, T1G3 with CIS in prostatic urethra, unusual histology of urothelial carcinoma, LVI (see Sections 4.6 and 6.2).	Radical cystectomy should be considered in those who refuse RC, intravesical full-dose BCG instillations for 1-3 years.
	BCG failures	Radical cystectomy is recommended.

BCG = bacillus Calmette-Guérin; CIS = carcinoma in situ; GR = grade of recommendation; HG = high-grade; LG = low-grade; LVI = lymphovascular invasion.

Table 7.4: Treatment recommendations for BCG failure and recurrences after BCG

Category	Treatment recommendation	GR
BCG-refractory tumour	1. Radical cystectomy 2. Bladder-preserving strategies in patients unsuitable for cystectomy	B
HG recurrence after BCG	1. Radical cystectomy 2. Repeat BCG course 3. Bladder-preserving strategies	C
Non-HG recurrence after BCG for primary intermediate-risk tumour	1. Repeat BCG or intravesical chemotherapy 2. Radical cystectomy	C

BCG = bacillus Calmette-Guérin; GR = grade of recommendation; HG = high-grade.

7.5 Recommendations for adjuvant therapy in Ta, T1 tumours and for therapy of CIS

	GR
Smokers with confirmed NMIBC should be counselled to stop smoking.	B
The type of further therapy after BCG should be based on the risk groups shown in Tables 6.3 and 7.3.	A
In patients with tumours presumed to be at low- or intermediate risk, one immediate chemotherapy instillation is recommended.	A
In patients with low-risk tumours, one immediate instillation of chemotherapy is recommended as the complete adjuvant treatment.	A
In patients with intermediate-risk tumours, one immediate instillation of chemotherapy should be followed by 1-year full-dose BCG treatment, or by further instillation of chemotherapy for a maximum of 1 year. The final choice should reflect the individual patient's risk of recurrence and progression as well as the efficacy and side effects of each treatment modality.	A
In patients with high-risk tumours, full-dose intravesical BCG for 1-3 years is indicated. The additional beneficial effect of the second and third years of maintenance should be weighed against its added costs and inconvenience.	A
In patients with CIS in the epithelial lining of the prostatic urethra, TUR of the prostate followed by intravesical instillation of BCG can be offered.	C
In patients at highest risk of tumour progression (Table 7.3), immediate radical cystectomy should be considered.	C
In patients with BCG failure, radical cystectomy is indicated.	B
Intravesical chemotherapy	
One immediate instillation of chemotherapy should be administered within 24 hours after TURB.	C
One immediate instillation of chemotherapy should be omitted in any case of overt or suspected intra- or extra-peritoneal perforation (after extensive TURB, or bleeding requiring bladder irrigation).	C
Give clear instructions to the nursing staff to control the free flow of the bladder catheter at the end of the immediate instillation.	C
The optimal schedule of further intravesical chemotherapy instillation and its duration is not defined, but it should not exceed 1 year.	C
If intravesical chemotherapy is given, it is advised to use the drug at its optimal pH and to maintain the concentration of the drug by reducing fluid intake before and during instillation.	B
The length of an individual instillation should be 1-2 hours.	C
BCG intravesical immunotherapy	
Absolute contraindications of BCG intravesical instillation are: <ul style="list-style-type: none"> • during the first 2 weeks after TURB; • in patients with visible haematuria; • after traumatic catheterisation; • in patients with symptomatic urinary tract infection. 	C
The management of side effects after BCG intravesical instillation should reflect their type and grade (Table 7.1).	C

BCG = *bacillus Calmette-Guérin*; CIS = *carcinoma in situ*; GR = *grade of recommendation*;

MMC = *mitomycin C*; TUR = *transurethral resection*; TURB = *transurethral resection of the bladder*.

8. FOLLOW-UP OF PATIENTS WITH NMIBC

As a result of the risk of recurrence and progression, patients with NMIBC need to be followed up. However, the frequency and duration of cystoscopy and imaging should reflect the individual patient's degree of risk. Using risk tables (see Tables 6.1 and 6.2), the short- and long-term risks of recurrence and progression in individual patients may be predicted and the follow-up schedule adapted accordingly [122, 123].

When planning the follow-up schedule and methods, the following aspects should be considered:

- The prompt detection of muscle-invasive and HG/G3 non-muscle-invasive recurrence is crucial because a delay in diagnosis and therapy can be life-threatening.
- Tumour recurrence in the low-risk group is nearly always low stage and LG/G1. Small, Ta LG/G1 papillary recurrence does not present an immediate danger to the patient and early detection is not essential for successful therapy [234-238] (LE: 2b). Fulguration of small papillary recurrences on

- an outpatient basis could be a safe option that reduces the therapeutic burden [90] (LE: 3). Some authors have even defended temporary surveillance in selected cases [237-239] (LE: 3).
- The first cystoscopy after TURB at 3 months is a very important prognostic indicator for recurrence and progression [128, 134, 240-242] (LE: 1a). Therefore, the first cystoscopy should always be performed 3 months after TURB in all patients with Ta, T1 tumours and CIS.
 - In tumours at low-risk, the risk of recurrence after 5 recurrence-free years is low [241] (LE: 3). Discontinuation of cystoscopy or its replacement with less-invasive methods can be considered [242].
 - In tumours originally intermediate- or high-risk, recurrences after 10 years tumour-free are not unusual [243] (LE: 3). Therefore, life-long follow-up is recommended [242].
 - The follow-up strategy must reflect the risk of extravesical recurrence (prostatic urethra in men and UUT)
 - The risk of UUT recurrence increases in patients with multiple- and high-risk tumours [55] (LE: 3).
 - Positive urine test results have a positive impact on the quality of performed follow-up cystoscopy [82] (LE: 1b). It supports the adjunctive role of urine tests during follow-up.

No non-invasive method has been proposed that can replace endoscopy and follow-up is therefore based on regular cystoscopy (see Section 5.7). There is a lack of randomized studies that have investigated the possibility of safely reducing the frequency of follow-up cystoscopy.

As CIS is often not visible, multiple biopsies may be necessary in selected cases to confirm the efficacy of intravesical treatment in patients treated for CIS [83].

The following recommendations are based mostly on retrospective data.

8.1 Guidelines for follow-up in patients after TURB of NMIBC

	GR
The follow-up of Ta, T1 tumours and CIS is based on regular cystoscopy.	A
Patients with low-risk Ta tumours should undergo cystoscopy at 3 months. If negative, subsequent cystoscopy is advised 9 months later, and then yearly for 5 years.	C
Patients with high-risk tumours should undergo cystoscopy and urinary cytology at 3 months. If negative, subsequent cystoscopy and cytology should be repeated every 3 months for a period of 2 years, and every 6 months thereafter until 5 years, and then yearly.	C
Patients with intermediate-risk Ta tumours should have an in-between follow-up scheme using cystoscopy and cytology, which is adapted according to personal and subjective factors.	C
Regular (yearly) upper tract imaging (CT-IVU or IVU) is recommended for high-risk tumours.	C
Endoscopy under anaesthesia and bladder biopsies should be performed when office cystoscopy shows suspicious findings or if urinary cytology is positive.	B
Consider R-biopsies or biopsies with PDD after intravesical treatment (at 3 or 6 months) in patients with CIS.	C
During follow-up in patients with positive cytology and no visible tumour in the bladder, R-biopsies or biopsies with PDD (if equipment is available) and investigation of extravesical locations (CT urography, prostatic urethra biopsy) are recommended.	B

CIS = carcinoma in situ; CT-IVU = computed tomography intravenous urography; GR = grade of recommendation; IVU = intravenous urography; PDD = photodynamic diagnosis; R-biopsies = random biopsies.

9. REFERENCES

1. Roupřet M, Babjuk M, Compérat E, et al. EAU Guidelines on Urothelial Carcinomas of the Upper Urinary Tract. In: EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2015. European Association of Urology, Arnhem, The Netherlands. ISBN 978-90-79754-80-9.
2. Witjes JA, Compérat E, Cowan NC, et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. In: EAU Guidelines. Edition presented at the EAU Annual Congress Madrid 2015. European Association of Urology, Arnhem, The Netherlands. ISBN 978-90-79754-80-9.
3. Gakis G, Witjes JA, Compérat E, et al. Guidelines on Primary Urethral Carcinoma. Edition presented at the EAU Annual Congress Madrid 2015. European Association of Urology, Arnhem, The Netherlands. ISBN 978-90-79754-80-9.
4. Ferlay J, Bray F, Forman D, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 2010, International Agency for Research on Cancer: Lyon, France.
5. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol* 2013 Feb;63(2):234-41.
6. Bosetti C, Bertuccio P, Chatenoud L, et al. Trends in mortality from urologic cancers in Europe, 1970-2008. *Eur Urol* 2011 Jul;60(1):1-15.
7. Chavan S, Bray F, Lortier-Tieulent J, et al. International Variations in Bladder Cancer Incidence and Mortality. *Eur Urol* 2014 Jul;66(1):59-73.
8. Steinmaus C, Ferreccio C, Acevedo J, et al. Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure. *Cancer Epidemiol Biomarkers Prev* 2014 Aug;23(8):1529-38.
9. Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. *JAMA* 2011 Aug;306(7):737-45.
10. Martini T, Mayr R, Lodde M, et al. Validation of Risk Check Bladder Cancer ©, version 5.0 for risk-adapted screening of bladder cancer. *Urol Int* 2013;91(2):175-81.
11. Mir MC, Stephenson AJ, Grubb RL 3rd, et al. Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. *Cancer Epidemiol Biomarkers Prev* 2013 Dec;22(12):2241-9.
12. Rushton L, Huchings SJ, Fortunato L, et al. Occupational cancer burden in Great Britain. *Br J Cancer* 2012 Jun; 107 Suppl 1:S3-S7.
13. Samanic CM, Kogevinas M, Silverman DT, et al. Occupation and bladder cancer in a hospital-based case-control study in Spain. *Occup Environ Med* 2008 May;65(5):347-53.
14. Colt J, Friesen M, Stewart P, et al. 0084 A Case-control study of occupational exposure to metalworking fluids and bladder cancer risk among men. *Occup Environ Med* 2014 Jun;71 Suppl 1:A71.
15. Pesch B, Taeger D, Johnen G, et al. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. *Int Arch Occup Environ Health* 2014 Oct;87(7):715-24.
16. Rafnar T, Vermeulen SH, Sulem P, et al. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. *Hum Mol Genet* 2011 Nov;20(21):4268-81.
17. Ros MM, Bas Bueno-de-Mesquita HB, Büchner FL, et al. Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer* 2011 Jun;128(11): 2695-708.
18. Koutros S, Silverman DT, Baris D, et al. Hair dye use and risk of bladder cancer in the New England bladder cancer study. *Int J Cancer* 2011 Dec;129(12):2894-904.
19. Ros MM, Gago-Dominguez M, Aben KK, et al. Personal hair dye use and the risk of bladder cancer: a case-control study from The Netherlands. *Cancer Causes Control* 2012 Jul;23(7):1139-48.
20. Sobin LH, Gospodariwicz M, Wittekind C, eds. TNM classification of malignant tumours. UICC International Union Against Cancer. 7th edn. Wiley-Blackwell, 2009 Dec; pp. 262-265.
21. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. *Am J Surg Pathol* 1998 Dec;22(12):1435-48.
22. Sauter G, Algaba F, Amin M, et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein JI, Sesterhenn I, eds. *WHO classification of classification of tumours of the urinary system and male genital organs*. Lyon: IARCC Press, 2004, pp. 29-34.
23. MacLennan GT, Kirkali Z, Cheng L. Histologic grading of non-invasive papillary urothelial neoplasms. *Eur Urol* 2007 Apr;51(4):889-98.
24. van Rhijn BW, van Leenders GJ, Ooms BC, et al. The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. *Eur Urol* 2010 Jun;57(6):1052-7.
25. Pan CC, Chang YH, Chen KK, et al. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinic pathologic study of 1,515 cases. *Am J Clin Pathol* 2010 May;133(5):788-95.

26. Burger M, Van der AA MN, Van Oers JM, et al. Prediction of Progression of Non-Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study. *Eur Urol* 2008 Oct;54(4):835-43.
27. May M, Brookman-Amisshah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in Non-invasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation Classifications. *Eur Urol* 2010 May;57(5):850-8.
28. Otto W, Denzinger S, Fritsche HM, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. *BJU Int* 2011 Feb;107(3):404-8.
29. Sylvester R, van der Meijden A, Witjes JA, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. *Urology* 2005 Dec;66(6 Suppl 1):90-107.
30. Lamm DL, Herr HW, Jakse G, et al. Updated concepts and treatment of carcinoma in situ. *Urol Oncol* 1998 Jul-Oct;4(4-5):130-8.
31. Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 WHO/ISUP classification of urothelial neoplasms: practical choices for patient care. *J Urol* 2002 Sep;168(3):968-72.
32. Witjes JA, Moonen PMJ, van der Heijden AG. Review pathology in a diagnostic bladder cancer trial. *Urology* 2006 Apr;67(4):751-5.
33. Bol MG, Baak J, Buhr-Wildhagen S, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. *J Urol* 2003 Apr;169(4):1291-4.
34. Van der Meijden A, Sylvester R, Collette L, et al. The role and impact of pathology review on stage and grade assessment on stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials. *J Urol* 2000 Nov;164(5):1533-7.
35. Van Rhijn BWG, van der Kwast TH, Kakiashvili DM, et al. Pathological stage review is indicated in primary pT1 bladder cancer. *BJU Int* 2010 Jul;106(2):206-11.
36. Compérat E, Egevad L, Lopez-Beltran A, et al. An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heat maps. *Histopathology* 2013 Dec;63(6):756-66.
37. Orsola A, Trias I, Raventós CX, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. *Eur Urol* 2005 Aug;48(2):231-8, discussion 238.
38. Andius P, Johansson SL, Holmäng S. Prognostic factors in stage T1 bladder cancer: tumor pattern(solid or papillary) and vascular invasion more important than depth of invasion. *Urology* 2007 Oct;70(4):758-62.
39. van Rhijn BW, van der Kwast TH, Alkhateeb SS, et al. A new and highly prognostic system to discern T1 bladder cancer substage. *Eur Urol* 2012 Feb;61(2):378-84.
40. van Rhijn BW, Liu L, Vis AN, et al. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. *BJU Int* 2012 Oct;110(8):1169-76.
41. Kim HS, Kim M, Jeong CW, et al. Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: A systematic review and meta-analysis. *Urol Oncol* 2014 Nov;32(8):1191-9.
42. Cho KS, Seo HK, Joung JY, et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. *J Urol* 2009 Dec;182(6):2625-31.
43. Compérat E, Rouprêt M, Yaxley J, et al. Micropapillary urothelial carcinoma of the urinary bladder: aclinicopathological analysis of 72 cases. *Pathology* 2010 Dec;42(7):650-4.
44. Kamat AM. The case for early cystectomy in the treatment of non-muscle invasive micropapillary bladder carcinoma. *J Urol* 2006 Mar;175(3 Pt 1):881-5.
45. Amin A, Epstein JI. Non-invasive micropapillary urothelial carcinoma: a clinicopathologic study of 18cases. *Hum Pathol* 2012 Dec;43(12):2124-8.
46. Blochin EB, Park KJ, Tickoo SK, et al. Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection. *Mod Pathol* 2012 Nov;25(11):1534-42.
47. Wasco MJ, Daignault S, Zhang Y, et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. *Urology* 2007 Jul;70(1):69-74.
48. Frstrup N, Ulhøi BP, Birkenkamp-Demtröder K, et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. *Am J Pathol* 2012 May; 180(5):1824-34.
49. Palou J, Algaba F, Vera I, et al. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with no maintenance bacillus Calmette-Guérin. *Eur Urol* 2009 Nov;56(5):829-36.
50. van Rhijn BW, van der Kwast TH, Liu L, et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. *J Urol* 2012 Jan;187(1):310-4.

51. Nolte-Ernsting C, Cowan N. Understanding multislice CT urography techniques: many roads lead to Rome. *Eur Radiol* 2006 Dec;16(12):2670-86.
52. Goessl C, Knispel HH, Millar K, et al. Is routine excretory urography necessary at first diagnosis of bladder cancer? *J Urol* 1997 Feb;157(2):480-1.
53. Palou J, Rodriguez-Rubio F, Huguet J, et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumours. *J Urol* 2005 Sep;174(3):859-61.
54. Holmång S, Hedelin H, Anderstrom C, et al. Long-term follow-up of a bladder carcinoma cohort: routine follow-up urography is not necessary. *J Urol* 1998 Jul;160(1):45-8.
55. Millan-Rodriguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. *J Urol* 2000 Oct;164(4):1183-7.
56. Têtu B. Diagnosis of urothelial carcinoma from urine. *Mod Pathol* 2009 Jun;22 Suppl 2:S53-9.
57. Raitanen M-P, Aine R, Rintala E, et al; FinnBladder Group. Differences between local and review urinary cytology and diagnosis of bladder cancer. An interobserver multicenter analysis. *Eur Urol* 2002 Mar;41(3):284-9.
58. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumour markers beyond cytology: international consensus panel on bladder tumour markers. *Urology* 2005 Dec;66(6 Suppl 1):35-63.
59. Burton JL, Goepel JR, Lee JA. Demand management in urine cytology: a single cytospin slide is sufficient. *J Clin Pathol* 2000 Sep;53(9):718-9.
60. Nabi G, Greene D, O'Donnell MO. Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up? *J Clin Pathol* 2004 Apr;57(4):365-8.
61. Glas AS, Roos D, Deutekom M, et al. Tumour markers in the diagnosis of primary bladder cancer. A systematic review. *J Urol* 2003 Jun;169(6):1975-82.
62. Van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. *Eur Urol* 2005 Jun;47(6):736-48.
63. Vrooman OPJ, Witjes JA. Urinary markers in bladder cancer. *Eur Urol* 2008 May;53(5):909-16.
64. Lotan Y, Shariat SF, Schmitz-Drager BJ, et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. *Urol Oncol* 2010 Jul-Aug;28(4):441-8.
65. Van Rhijn BWG, van der Poel HG, van der Kwast HG. Cytology and urinary markers for the diagnosis of bladder cancer. *Eur Urol Suppl* 2009;8:536-41.
66. Catto JWF. Old and new urinary markers: Which one is the PSA for bladder cancer? *Eur Urol Suppl* 2008 Feb;7:422-5.
67. Yutkin V, Nisman B, Pode D. Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance? *Expert Rev Anticanc* 2010 Jun;10(6):787-90.
68. Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. *World J Urol* 2008 Feb;26(1):39-44.
69. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. *Urol Oncol* 2008 Nov-Dec;26(6):645-51.
70. Schlomer BJ, Ho R, Sagalowsky A, et al. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. *J Urol* 2010 Jan;183(1):62-7.
71. Kamat AM, Karam JA, Grossman HB, et al. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. *BJU Int* 2011 Oct;108(7):1119-23.
72. Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. *Urol Oncol* 2014 Jul 15. pii: S1078-1439(14)00214-2. doi: 10.1016/j.urolonc.2014.06.008. [Epub ahead of print]
73. Bergman J, Reznicek RC, Rajfer J. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. *BJU Int* 2008 Jan;101(1):26-9.
74. Van der Aa MN, Zwarthoff EC, Steyerberg EW, et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). *Eur Urol* 2009 Mar;55(3):659-67.
75. De Bekker-Grob EW, van der Aa MN, Zwarthoff EC, et al. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative? *BJU Int* 2009 Jul;104(1):41-7.
76. Rouprêt M, Hupertan V, Yates DR, et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. *BJU Int* 2008 Jun;101(11):1448-53.
77. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. *JAMA* 2005 Feb;293(7):810-6.
78. Lotan Y, Svatek RS, Malats N. Screening for bladder cancer: a perspective. *World J Urol* 2008 Feb;26(1):13-8.

79. Roobol MJ, Bangma CH, el Bouazzaoui S, et al. Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). *Urol Oncol* 2010 Nov-Dec;28(6):686-90.
80. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. *JAMA* 2006 Jan;295(3):299-305.
81. Babjuk M, Soukup V, Pesl M, et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pT1 bladder urothelial carcinoma. *Urology* 2008 Apr;71(4):718-22.
82. van der Aa MN, Steyerberg EW, Bangma C, et al. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. *J Urol* 2010 Jan;183(1):76-80.
83. Kurth KH, Schellhammer PF, Okajima E, et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. *Int J Urol* 1995 Jun;2 Suppl 2:8-22.
84. Aaronson DS, Walsh TJ, Smith JF, et al. Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief? *BJU Int* 2009 Aug;104(4):506-9; discussion 509-10.
85. Richterstetter M, Wullich B, Amann K, et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. *BJU Int* 2012 Jul;110(2 Pt 2):E76-9.
86. Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. *BJU Int* 2008 Nov;102(9 Pt B):1242-6.
87. Brausi M, Collette L, Kurth K, et al; EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. *Eur Urol* 2002 May;41(5):523-31.
88. Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. *Eur Urol* 2010 May;57(5):843-9.
89. Mariappan P, Finney SM, Head E, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. *BJU Int* 2012 Jun;109(11):1666-73.
90. Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. *J Urol* 2007 Oct;178(4 Pt 1):1201-5.
91. Gupta NP, Saini AK, Dogra PN, et al. Bipolar energy for transurethral resection of bladder tumours at low-power settings: initial experience. *BJU Int* 2011 Aug;108(4):553-6.
92. Venkatramani V, Panda A, Manojkumar R, et al. Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. *J Urol* 2014 Jun;191(6):1703-7.
93. Sugihara T, Yasunaga H, Horiguchi H, et al. Comparison of perioperative outcomes including severe bladder injury between monopolar and bipolar transurethral resection of bladder tumors: A Population Based Comparison. *J Urol* 2014 Nov;192(5):1355-9.
94. Mashni J, Godoy G, Haarer C, et al. Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. *Int Urol Nephrol* 2014 Sep;46(9):1699-705.
95. Van der Meijden A, Oosterlinck W, Brausi M, et al. Significance of bladder biopsies in Ta, T1 bladder tumours: a report of the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. *Eur Urol* 1999 Apr;35(4):267-71.
96. Hara T, Takahashi M, Gondo T, et al. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases. *Int J Urol* 2009 Mar;16(3):293-8.
97. Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. *Eur Urol* 2012 Jul;62(1):118-25.
98. Mungan MU, Canda AE, Tuzel E, et al. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. *Eur Urol* 2005 Nov;48(5):760-3.
99. Huguet J, Crego M, Sabaté S, et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. *Eur Urol* 2005 Jul;48(1):53-9; discussion 59.
100. Kausch I, Sommerauer M, Montorsi F, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. *Eur Urol* 2010 Apr;57(4):595-606.
101. Mowatt G, N'Dow J, Vale L, et al; Aberdeen Technology Assessment Review (TAR) Group. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. *Int J Technol Assess Health Care* 2011 Jan;27(1):3-10.
102. Draga RO, Grimbergen MC, Kok ET, et al. Photodynamic diagnosis (5 aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy. *Eur Urol* 2010 Apr;57(4):655-60.

103. Ray ER, Chatterton K, Khan MS, et al. Hexylaminolevulinic acid fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin. *BJU Int* 2010 Mar;105(6):789-94.
104. Schumacher MC, Holmäng S, Davidsson T, et al. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. *Eur Urol* 2010 Feb;57(2):293-9.
105. Stenzl A, Penkoff H, Dajc-Sommerer E, et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter, randomized, double-blind, placebo-controlled trial. *Cancer* 2011 Mar;117(5):938-47.
106. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinic acid cystoscopy: a meta-analysis of detection and recurrence based on raw data. *Eur Urol* 2013 Nov;64(5): 846-54.
107. O'Brien T, Ray E, Chatterton K, et al. Prospective randomized trial of hexaminolevulinic acid photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. *BJU Int* 2013 Dec;112(8):1096-104.
108. Cauberg EC, Kloen S, Visser M, et al. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. *Urology* 2010 Sep;76(3):658-63.
109. Zheng C, Lv Y, Zhong Q, et al. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. *BJU Int* 2012 Dec;110(11 Pt B):E680-7.
110. Herr HW. Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors. *Eur Urol* 2014 Jul 17. pii: S0302-2838(14)00623-X. doi: 10.1016/j.eururo.2014.06.049. [Epub ahead of print].
111. Grimm M-O, Steinhoff Ch, Simon X, et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. *J Urol* 2003 Aug;170(2 Pt 1):433-7.
112. Divrik RT, Yildirim Ü, Zorlu F, et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumours of the bladder who received intravesical mitomycin: prospective, randomized clinical trial. *J Urol* 2006 May;175(5):1641-4.
113. Jahnsen S, Wiklund F, Duchek M, et al. Results of second-look resection after primary resection of T1 tumour of the urinary bladder. *Scand J Urol Nephrol* 2005;39(3):206-10.
114. Lazica DA, Roth S, Brandt AS, et al. Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. *Urol Int* 2014;92(2):131-5.
115. Vasdev N, Dominguez-Escrig J, Paez E, et al. The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer. *Ecancelmedscience*. 2012;6:269.
116. Dalbagni G, Vora K, Kaag M, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. *Eur Urol* 2009 Dec;56(6):903-10.
117. Fritsche HM, Burger M, Svatek RS, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *Eur Urol* 2010 Feb;57(2):300-9.
118. Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. *Eur Urol* 2010 Jan;57(1):60-70.
119. Sfakianos JP, Kim PH, Hakimi AA, et al. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle Invasive bladder cancer treated with intravesical bacillus Calmette-Guerin. *J Urol* 2014 Feb;191(2):341-5.
120. Bishr M, Lattouf JB, Latour M, et al. Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. *Can Urol Assoc J* 2014 May;8(5-6):E306-10.
121. Lopez-Beltran A, Bassi P, Pavone-Macaluso M, et al. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. *Eur Urol* 2004 Mar;45(3):257-66.
122. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta, T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *Eur Urol* 2006 Mar;49(3):466-5.
123. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. *J Urol* 2009 Nov;182(5):2195-203.
124. Van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. *Eur Urol* 2010 Sep;58(3):433-41.
125. Fernandez-Gomez J, Madero R, Solsona E, et al; Club Urológico Español de Tratamiento Oncológico. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. *Eur Urol* 2011 Sep;60(3):423-30.

126. Gontero P, Sylvester R, Pisano F, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: Results of a retrospective multicenter study of 2451 patients. *Eur Urol* 2015 Jan;67(1):74-82.
127. Golijanin D, Yossepowitch O, Beck SD, et al. Carcinoma in a bladder diverticulum: presentation and treatment outcome. *J Urol* 2003 Nov;170(5):1761-4.
128. Palou J, Rodríguez-Rubio F, Millán F, et al. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. *Urology* 2009 Jun;73(6):1313-7.
129. Alkhateeb SS, Neill M, Bar-Moshe S, et al. Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. *Urol Ann* 2011 Sep;3(3):119-26.
130. Lamm DL. Carcinoma in situ. *Urol Clin North Am* 1992 Aug;19(3):499-508.
131. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. *J Urol* 2000 Jan;163(1):68-72.
132. Griffiths TRL, Charlton M, Neal DE, et al. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. *J Urol* 2002 Jun;167(6):2408-12.
133. Takenaka A, Yamada Y, Miyake H, et al. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. *Int J Urol* 2008 Apr;15(4):309-13.
134. Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. *J Urol* 2000 Sep;164(3 Pt 1):685-9.
135. Van Gils-Gielen RJ, Witjes WP, Caris CT, et al. Risk factors in carcinoma in situ of the urinary bladder. *Urology* 1995 Apr;45(4):581-6.
136. Lammers RJ, Witjes WP, Hendricksen K, et al. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. *Eur Urol* 2011 Oct;60(4):713-20.
137. Rink M, Xylinas E, Babjuk M, et al. Smoking reduces the efficacy of intravesical bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer. *Eur Urol* 2012 Dec;62(6):1204-6.
138. Rink M, Xylinas E, Babjuk M, et al. Impact of smoking on outcomes of patients with a history of recurrent non-muscle invasive bladder cancer. *J Urol* 2012 Dec;188(6):2120-7.
139. Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. *Eur Urol* 2014 Apr;65(4):742-54.
140. Grotenhuis AJ, Ebben CW, Aben KK, et al. The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. *Urol Oncol*. 2014 Jul 9. pii: S1078-1439(14)00208-7. doi: 10.1016/j.urolonc.2014.06.002 [Epub ahead of print].
141. Serretta V, Altieri V, Morgia G, et al. Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. *Urology* 2013 Feb;81(2):277-81.
142. Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. *Cancer* 1980 Sep;46(5):1158-63.
143. Pan JS, Slocum HK, Rustum YM, et al. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. *J Urol* 1989 Dec;142(6):1589-93.
144. Brocks CP, Büttner H, Böhle A. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. *J Urol* 2005 Sep;174(3):1115-8.
145. Oosterlinck W, Kurth KH, Schröder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. *J Urol* 1993 Apr;149(4):749-52.
146. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. *J Urol* 2004 Jun;171(6 Pt 1):2186-90.
147. Abern MR, Owusu RA, Anderson MR, et al. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. *J Natl Compr Canc Netw* 2013 Apr;11(4):477-84.
148. Perlis N, Zlotta AR, Beyene J, et al. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. *Eur Urol* 2013 Sep;64(3):421-30.
149. Berrum-Svennung I, Granfors T, Jahnsen S, et al. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. *J Urol* 2008 Jan;179(1):101-5.
150. Gudjonsson S, Adell L, Merdasa F, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. *Eur Urol* 2009 Apr;55(4):773-80.

151. Bouffieux C, Kurth KH, Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. *J Urol* 1995 Mar;153(3 Pt 2):934-41.
152. Kaasinen E, Rintala E, Hellstrom P, et al; FinnBladder Group. Factors explaining recurrence in patients undergoing chemo-immunotherapy regimens for frequently recurring superficial bladder carcinoma. *Eur Urol* 2002 Aug;42(2):167-74.
153. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non muscle invasive bladder cancer: a systematic review of the published results of randomized clinical trials. *Eur Urol* 2008 Apr;53(4):709-19.
154. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. *J Urol* 1996 Apr;155(4):1233-8.
155. Pode D, Alon Y, Horowitz AT, et al. The mechanism of human bladder tumor implantation in an in vitro model. *J Urol* 1986 Aug;136(2):482-6.
156. Günther JH, Jurczok A, Wulf T, et al. Optimizing syngeneic orthotropic murine bladder cancer (MB49). *Cancer Res* 1999 Jun;59(12):2834-7.
157. Böhle A, Jurczok A, Ardelt PU, et al. Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo. *J Urol* 2002 Jan;167(1):357-63.
158. Oddens JR, van der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? *Eur Urol* 2004 Sep;46(3):336-8.
159. Elmamoun MH, Christmas TJ, Woodhouse CR. Destruction of the bladder by single dose Mitomycin C for low-stage transitional cellcarcinoma (TCC) – avoidance, recognition, management and consent. *BJU Int* 2014 May;113(5b):E34-8.
160. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. *Anticancer Res* 2001 Jan-Feb; 21(1B):765-9.
161. Böhle A, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. *Urology* 2004 Apr;63(4):682-6. Discussion 686-7.
162. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. *J Urol* 2002 Nov;168(5):1964-70.
163. Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the longterm outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. *Eur Urol* 2009 Aug;56(2):247-56.
164. Sylvester RJ, Brausi MA, Kirkels WJ, et al; EORTC Genito-Urinary Tract Cancer Group. Longterm efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. *Eur Urol* 2010 May;57(5):766-73
165. Shang PF, Kwong J, Wang ZP, et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta andT1 bladder cancer. *Cochrane Database Syst Rev* 2011 May 11;(5):CD006885.
166. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. *Eur Urol* 2011 Jul;60(1):81-93.
167. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *Lancet Oncol* 2006 Jan;7(1):43-51.
168. Au JL, Baladament RA, Wientjes MG, et al; International Mitomycin C Consortium. International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. *J Natl Cancer Inst* 2001 Apr;93(8):597-604.
169. Giesbers AA, Van Helsdingen PJ, Kramer AE. Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times. *Br J Urol* 1989 Feb;63(2):176-9.
170. Kuroda M, Nijijima T, Kotake T, et al; 6th Trial of the Japanese Urological Cancer Research Group. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer-The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30 mg/40 ml, 40 mg/40 ml. *Eur Urol* 2004 May;45(5):600-5.
171. Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. *BJU Int* 2001 Aug;88(3): 209-16.
172. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. *Urology* 2006 Jun;67(6):1216-23.

173. Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a metaanalysis of randomized trials. *BJU Int* 2004 Mar;93(4):485-90.
174. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. *J Urol* 2003 Jan;169(1):90-5.
175. Duchek M, Johansson R, Jahnson S, et al. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon- α 2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. *Eur Urol* 2010 Jan;57(1):25-31.
176. Järvinen R, Kaasinen E, Sankila A, et al. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent Ta, T1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. *Eur Urol* 2009 Aug;56(2):260-5.
177. Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. *Am J Clin Oncol* 2004 Oct;27(5):522-8.
178. Oddens JR, Sylvester RJ, Brausi MA, et al. The effect of age on the efficacy of maintenance Bacillus Calmette-Guérin relative to maintenance Epirubicin in patients with Stage Ta T1 urothelial bladder cancer: Results from EORTC Genito-Urinary Group Study 30911. *Eur Urol* 2014 Oct;66(4):694-701.
179. Houghton BB, Chalasani V, Hayne D, et al.: Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. *BJU Int* 2013 May;111(6):977-83.
180. Rentsch CA, Birkhäuser FD, Biot C, et al. bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. *Eur Urol* 2014 Oct;66(4):677-88.
181. Sengiku A, Ito M, Miyazaki Y, et al. A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught Strain for nonmuscle invasive bladder cancer. *J Urol* 2013 Jul;190(1):50-4.
182. Van der Meijden AP, Sylvester RJ, Oosterlinck W, et al; EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta, T1 bladder tumours is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. *Eur Urol* 2003 Oct;44(4):429-34.
183. Brausi M, Oddens J, Sylvester R, et al. Side effects of bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC Genito-Urinary Cancers Group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. *Eur Urol* 2014 Jan;65(1):69-76.
184. Herr HW. Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria. *J Urol* 2012 Feb;187(2):435-7.
185. Herr HW. Outpatient urological procedures in antibiotic-naïve patients with bladder cancer with asymptomatic bacteriuria. *BJU Int* 2012 Dec;110(11 Pt B):E658-60.
186. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. *J Urol* 1992 Mar;147(3):596-600.
187. Palou J, Angerri O, Segarra J, et al. Intravesical bacillus Calmette-Guérin for the treatment of superficial bladder cancer in renal transplant patients. *Transplantation* 2003 Nov;76(10):1514-6.
188. Yossepowitch O, Eggener SE, Bochner BH, et al. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. *J Urol* 2006 Aug;176(2):482-5.
189. Rodríguez F, Palou J, Martínez R, et al. [Practical guideline for the management of adverse events associated with BCG installations.] *Arch Esp Urol* 2008 Jun;61(5):591-6. [Article in Spanish]
190. Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. *Eur Urol Suppl* 2008 Oct;7(10):667-74.
191. Palou J, Rodríguez-Villamil L, Andreu-Crespo A, et al. Intravesical treatment of severe bacillus Calmette-Guerin cystitis. *Int Urol Nephrol* 2001;33(3):485-9.
192. Falkensammer C, Gozzi C, Hager M, et al. Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guerin therapy for superficial bladder carcinoma. *Urology* 2005 Jan;65(1):175.
193. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. *Rheumatol Int* 2006 Apr;26(6):481-8.
194. Morales, A, Eiding D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. *J Urol* 1976 Aug;116(2):180-3.
195. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. *J Urol* 2000 Apr;163(4):1124-9.
196. Zlotta AR, van Vooren JP, Huygen K, et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? *Eur Urol* 2000 Apr;37(4):470-7.

197. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. *Eur Urol* 2013 Mar;63(3):462-72.
198. Martínez-Piñero JA, Flores N, Isorna S, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer. *BJU Int* 2002 May;89(7):671-80.
199. Martínez-Piñero JA, Martínez-Piñero L, Solsona E, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. *J Urol* 2005 Oct;174(4 Pt 1):1242-7.
200. Ojea A, Nogueira JL, Solsona E, et al; CUETO Group (Club Urológico Español De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C. *Eur Urol* 2007 Nov;52(5):1398-406.
201. Jakse G, Hall R, Bono A, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. *Eur Urol* 2001 Aug;40(2):144-50.
202. Gofrit ON, Pode D, Pizov G, et al. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guérin immunotherapy. *Urol Oncol* 2009 May-Jun;27(3):258-62.
203. Sylvester RJ, van der Meijden APM, Witjes JA, et al. Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. *J Urol* 2005 Jul;174(1):86-92.
204. Kaasinen E, Wijkstrom H, Malmstrom PU, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. *Eur Urol* 2003 Jun;43(6):637-45.
205. Solsona E, Iborra I, Ricos JV, et al. Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. *J Urol* 1996 Mar;155(3):895-9.
206. Palou J, Baniel J, Klotz L, et al. Urothelial carcinoma of the prostate. *Urology* 2007 Jan;69(1 Suppl):50-61.
207. Palou Redorta J, Schatteman P, Huguet Pérez J, et al. Intravesical instillations with bacillus calmette guérin for the treatment of carcinoma in situ involving prostatic ducts. *Eur Urol* 2006 May;49(5):834-8;discussion 838.
208. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumours. *J Urol* 2003 May;169(5):1706-8.
209. Lerner SP, Tangen CM, Sucharew H, et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. *Urol Oncol* 2009 Mar-Apr;27(2):155-9.
210. van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. *Eur Urol* 2011 Sep;60(3):493-500.
211. Gallagher BL, Joudi FN, Maymi JL, et al. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. *Urology* 2008 Feb;71(2):297-301.
212. Rosevear HM, Lightfoot AJ, Birusingh KK, et al. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ. *J Urol* 2011 Sep;186(3):817-23.
213. Yates DR, Brausi MA, Catto JW, et al. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. *Eur Urol* 2012 Dec;62(6):1088-96.
214. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. *J Clin Oncol* 2006 Jun;24(18):2729-34.
215. Mohanty NK, Nayak RL, Vasudeva P, et al. Intravesical gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. *Urol Oncol* 2008 Nov-Dec;26(6):616-9.
216. Barlow L, McKiernan J, Sawczuk I, et al. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacilli Calmette-Guerin therapy. *BJU Int* 2009 Oct;104(8):1098-102.
217. Steinberg G, Bahnon R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. *J Urol* 2000 Mar;163(3):761-7.
218. Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. *J Urol* 2009 Oct;182(4):1313-7.
219. Joudi FN, Smith BJ, O'Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. *Urol Oncol* 2006 Jul-Aug;24(4):344-8.
220. Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. *Cancer* 2010 Apr;116(8):1893-900.

221. Jones G, Cleves A, Wilt TJ, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. *Cochrane Database Syst Rev* 2012 Jan;1:CD009294.
222. Turker P, Bostrom PJ, Wroclawski ML, et al. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. *BJU Int* 2012 Sep;110(6):804-11.
223. Chalasani V, Kassouf W, Chin JL, et al. Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. *Can Urol Assoc J* 2011 Apr;5(2):83-7.
224. May M, Bastian PJ, Brookman-May S, et al. Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. *Scand J Urol Nephrol* 2011 Sep;45(4):251-7.
225. Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. *BJU Int* 2011 Mar;107(6):898-904.
226. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. *Eur Urol* 2007 Jan;51(1):137-49; discussion 149-51.
227. Bianco FJ Jr, Justa D, Grignon DJ, et al. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. *Urol Oncol* 2004 Jul-Aug;22(4):290-4.
228. Raj GV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. *J Urol* 2007 Apr;177(4):1283-6.
229. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol* 2001 Feb;19(3):666-75.
230. Hautmann RE, Gschwend JE, de Petriconi RC, et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. *J Urol* 2006 Aug;176(2):486-92; discussion 491-2.
231. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. *J Clin Oncol* 2003 Feb;21(4):690-6.
232. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium. *J Urol* 2006 Dec;176(6 Pt 1):2414-22.
233. Shariat SF, Palapattu GS, Amiel GE, et al. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. *Urology* 2006 Sep;68(3):538-42.
234. Holmäng S, Andius P, Hedelin H, et al. Stage progression in Ta papillary urothelial tumours: relationship to grade, immunohistochemical expression of tumour markers, mitotic frequency and DNA ploidy. *J Urol* 2001 Apr;165(4):1124-8.
235. Fujii Y, Kawakami S, Koga F, et al. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. *BJU Int* 2003 Oct;92(6):559-62.
236. Borhan A, Reeder JE, O'Connell MJ, et al. Grade progression and regression in recurrent urothelial cancer. *J Urol* 2003 Jun;169(6):2106-9.
237. Soloway M, Bruck DS, Kim SS. Expectant management of small recurrent, non-invasive papillary bladder tumours. *J Urol* 2003 Aug;170(2 Pt 1):438-41.
238. Gofrit ON, Pode D, Lazar A, et al. Watchful waiting policy in recurrent Ta G1 bladder tumours. *Eur Urol* 2006 Feb;49(2):303-6.
239. Pruthi RS, Baldwin N, Bhalani V, et al. Conservative management of low risk superficial bladder tumors. *J Urol* 2008 Jan;179(1):87-90.
240. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first follow-up cystoscopy and subsequent recurrence and progression. *J Urol* 2002 Apr;167(4):1634-7.
241. Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. *J Urol* 2005 Apr;173(4):1108-11.
242. Soukup V, Babjuk M, Bellmunt J, et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. *Eur Urol* 2012 Aug;62(2):290-302.
243. Holmäng S, Ströck V. Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years? *Eur Urol* 2012 Mar;61(3):503-7.

10. CONFLICT OF INTEREST

All members of the Non-Muscle-Invasive Bladder Cancer guidelines working group have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publically accessible through the European Association of Urology website: <http://www.uroweb.org/guidelines/>. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.